

**ENVIRONMENT DIRECTORATE
JOINT MEETING OF THE CHEMICALS COMMITTEE AND THE WORKING PARTY
ON CHEMICALS, PESTICIDES AND BIOTECHNOLOGY**

**REPORT OF THE VALIDATION STUDY AND REPORT OF THE PEER
REVIEW OF THE VALIDATION OF THE VITRIGEL EYE IRRITANCY TEST
METHOD IN TEST GUIDELINE 494**

**Series on Testing and Assessment
No. 301**

Document only available in PDF format.

JT03450431

SERIES ON TESTING AND ASSESSMENT
NO. 301

REPORT OF THE VALIDATION STUDY AND REPORT OF THE PEER REVIEW OF THE
VALIDATION OF THE VITRIGEL EYE IRRITANCY TEST METHOD IN TEST
GUIDELINE 494

IOMC

INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS

A cooperative agreement among **FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD**

Environment Directorate
ORGANISATION FOR ECONOMIC COOPERATION AND DEVELOPMENT
Paris 2019

About the OECD

The Organisation for Economic Co-operation and Development (OECD) is an intergovernmental organisation in which representatives of 35 industrialised countries in North and South America, Europe and the Asia and Pacific region, as well as the European Commission, meet to co-ordinate and harmonise policies, discuss issues of mutual concern, and work together to respond to international problems. Most of the OECD's work is carried out by more than 200 specialised committees and working groups composed of member country delegates. Observers from several countries with special status at the OECD, and from interested international organisations, attend many of the OECD's workshops and other meetings. Committees and working groups are served by the OECD Secretariat, located in Paris, France, which is organised into directorates and divisions.

The Environment, Health and Safety Division publishes free-of-charge documents in eleven different series: **Testing and Assessment; Good Laboratory Practice and Compliance Monitoring; Pesticides; Biocides; Risk Management; Harmonisation of Regulatory Oversight in Biotechnology; Safety of Novel Foods and Feeds; Chemical Accidents; Pollutant Release and Transfer Registers; Emission Scenario Documents; and Safety of Manufactured Nanomaterials.** More information about the Environment, Health and Safety Programme and EHS publications is available on the OECD's World Wide Web site (www.oecd.org/chemicalsafety/).

This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations.

The Inter-Organisation Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen co-operation and increase international co-ordination in the field of chemical safety. The Participating Organisations are FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote co-ordination of the policies and activities pursued by the Participating Organisations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment.

This publication is available electronically, at no charge.

**For this and many other Environment,
Health and Safety publications, consult the OECD's
World Wide Web site (www.oecd.org/chemicalsafety/)**

or contact:

**OECD Environment Directorate,
Environment, Health and Safety Division
2 rue André-Pascal
75775 Paris Cedex 16
France**

Fax: (33-1) 44 30 61 80

E-mail: ehscont@oecd.org

FOREWORD

This document contains two reports related to the Vitrigel Eye irritancy Test Method contained in Test Guideline 494:

- Annex 1: report of the validation study, performed by JaCVAM;
- Annex 2: report of the peer-review, performed by an independent panel of experts.

The two reports were circulated to the Working Group of the National Coordinators of the Test Guidelines Programme and OECD Expert Group on Eye Irritation in August 2018 for review in support of the draft Test Guideline on the Vitrigel Eye Irritancy Test Method.

In April 2019, the Working Group of the National Coordinators of the Test Guidelines Programme approved the new Test Guideline 494 on the Vitrigel test method, and endorsed the validation and peer-review reports presented in this document.

**Validation Study of the Vitrigel-EIT method
as an alternative to in vivo eye irritation testing**

Study Report, Version 2.1

July 4, 2018

VITRIGEL-EIT Validation Management Team (VMT)

Table of Contents

Abbreviations

- 1 Abstract
- 2 Introduction
- 3 Methods
 - 3.1 Study Plan
 - 3.1.1 Purpose
 - 3.1.2 Organization
 - 3.1.2.1 *Trial coordinator*
 - 3.1.2.2 *Chemical management group*
 - 3.1.2.3 *Data analysis group*
 - 3.1.2.4 *Record management group*
 - 3.1.2.5 *Lead laboratory*
 - 3.1.2.6 *Participating laboratories*
 - 3.1.3 Study design
 - 3.1.3.1 *Training of personnel at the participating laboratories*
 - 3.1.3.2 *Phase 0*
 - 3.1.3.2 *Phase I*
 - 3.1.3.3 *Phase II*
 - 3.1.3.4 *Phase III*
 - 3.1.4 Success criteria
 - 3.2 Summary of protocol
 - 3.2.1 Culturing HCE-T cells
 - 3.2.2 Preparation of collagen vitrigel membrane chambers
 - 3.2.3 Reconstruction of a human corneal epithelium model
 - 3.2.4 Mode of action in vivo
 - 3.2.5 Calculation of TEER values for HCE models
 - 3.2.6 Exposure to test chemicals
 - 3.2.7 Calculating eye irritancy of test chemicals
 - 3.2.8 Correlation with the UN GHS classification
 - 3.2.9 Commercial availability and/or intellectual property rights to the test method and its components
 - 3.3 Test chemicals
 - 3.3.1 Selection and distribution of test chemicals
 - 3.3.2 Test chemicals for Phases 0, I, II, and III
 - 3.3.2.1 *Test chemicals for Phase 0*
 - 3.3.2.2 *Test chemicals for Phase I*
 - 3.3.2.3 *Test chemicals for Phase II*
 - 3.3.2.4 *Test chemicals for Phase III*
 - 3.4 Quality assurance

- 3.5 Record collection and analysis
- 4 Results
 - 4.1 Study duration
 - 4.1.1 Phase 0
 - 4.1.2 Phase I
 - 4.1.3 Phase II
 - 4.1.4 Phase III
 - 4.2 Quality assurance
- 5 Discussion
 - 5.1 Purpose of the Validation
 - 5.2 Transferability
 - 5.3 Within- and between-laboratory reproducibility
 - 5.4 Predictive capacity and relevance
 - 5.5 Applicability domain
 - 5.6 Other analysis
 - 5.7 Comparison with other alternative to ocular irritation assay
- 6 Conclusion
- 7 References
- 8 Appendix
 - 8.1 Study Plan ver.4
 - 8.2 Protocol ver.1.80e
 - 8.3 Data sheet format
 - 8.4 Selection of test chemicals
 - 8.5 Statistical analysis report for Vitrigel-EIT validation study
 - 8.6 Report on the Quality assurance for Vitrigel-EIT validation study
 - 8.7 Minutes of VMT meetings
 - 8.8 Result of the Vitrigel-EIT at the lead laboratory for 114 chemicals
 - 8.9 The draft list of proficiency chemicals
 - 8.10 Yamaguchi H, et al., 2016. J. Applied Toxicology accepted
 - 8.11 The raw data for the 114 in-house chemicals
 - 8.12 Background by biostatistician

Abbreviations

CVM	Collagen Vitrigel Membrane
EIT	Eye Irritancy Test
EURL ECVAM	European Union Reference Laboratory for Alternatives to Animal Testing
ECETOC	European Centre for Ecotoxicology and Toxicology of Chemicals
GHS	Globally Harmonized Systems of Classification and Labeling

GLP	Good Laboratory Practice
HCE	Human Corneal Epithelium
ICCVAM	Interagency Coordinating Committee on the Validation of Alternative Methods
JaCVAM	Japanese Centre for the Validation of Alternative Methods
NI	Non-irritant
NICEATM	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods
OECD	Organization for Economic Co-operation and Development
PET	Polyethylene terephthalate
SOP	Standard operating procedure
STE	Short time exposure
TEER	Transepithelial electrical resistance
UN	United Nations
VMT	Validation management team

1 Abstract

Collagen vitrigel membrane (CVM) comprises high-density collagen fibrils that are equivalent to in vivo connective tissues and is easily handled with tweezers. Takezawa et al. developed a human corneal epithelium (HCE) model by three-dimensional culturing of HCE-T cells on a CVM scaffold in a chamber that provided an air-liquid interface culture system. They further used their HCE model to establish a new test method, known as the Vitrigel-eye irritancy test (Vitrigel-EIT) method, which can be used to estimate the ocular irritation potential of test chemicals by analyzing relative changes in transepithelial electrical resistance (TEER) over time.

This trial was conducted to validate the reliability and relevance of the Vitrigel-EIT method at three participating laboratories in the spirit of GLP by verifying the within- and between-laboratory reproducibility for 42 test chemicals as well as the capacity for distinguishing non-irritants from irritants in a bottom-up approach.

The results showed 80–100% within-laboratory reproducibility at all three laboratories and an excellent between-laboratory reproducibility of 92%. Unfortunately, the predictive capacity for distinguishing non-irritants from irritants per UN GHS categories in a bottom-up approach was not favorable because of false negative rates as high as 13% with in house data. After considerable review of the data, however, it was determined that excluding test chemicals with a pH level of 5 or less as well as solid test chemicals with a logP value of 2.5 or more and a density of less than 0.95 g/cm³ or greater than 1.10 g/cm³ improved the false negative rate to as low as 2%.

These results suggest that, with a carefully defined applicability domain, the Vitrigel-EIT method is a useful alternative to the Draize test for distinguishing test chemicals that are ocular non-irritants from those that are irritants.

2 Introduction

Collagen vitrigel membrane (CVM) comprises high-density collagen fibrils that are equivalent to *in vivo* connective tissues and is easily handled with tweezers. In addition, it has excellent transparency and permeability of high molecular weight proteins and is now used as a cell culture scaffold in a number of advanced studies (Takezawa et al., 2004, 2007a–c). Takezawa et al. developed a corneal epithelium model utilizing a CVM scaffold that facilitates the maintenance of corneal epithelial phenotype in a monolayer of rabbit corneal epithelial cells (Takezawa et al., 2008). Still, there are significant differences in sensitivity to exogenous chemicals between humans and rabbits, so they also developed a human corneal epithelium (HCE) model by three-dimensional culturing of HCE-T cells on the CVM scaffold in a chamber that provided an air–liquid interface culture system (Takezawa et al., 2011a). Here, HCE-T cells are a SV40-immortalized cell strain established by Araki-Sasaki et al (Araki-Sasaki et al., 1995). The HCE-T cell line is one of the most favored human cornea epithelium-derived cells and frequently used for various cornea epithelium-related studies because it is easy to maintain the stable characteristics of cornea epithelial cells in culture (Kim et al., 2016, Yamasaki et al., 2009). The scaffold was fabricated on a polyethylene terephthalate (PET) membrane of a Millicell chamber suitable for assaying the transepithelial electrical resistance (TEER) of epithelial cells. The TEER assay is considered a suitable method for *in vivo* evaluation of the integrity of the tight junction of the corneal epithelium (Uematsu et al., 2007). Takezawa et al. then used the HCE model to verify that relative change over time in TEER is a useful indicator for assessing the ocular irritancy of four test chemicals, including mild irritants (Takezawa et al., 2011a). The HCE model, however, is not considered suitable for immuno-histological analyses due to difficulties in preparing frozen sections with a PET membrane. To overcome this inconvenience, they developed a novel chamber that merely accompanies a CVM without the PET membrane as well as established a process for its mass production (Takezawa et al., 2011b, 2012). More recently, they established a new test method for estimating the ocular irritancy of test chemicals by analyzing the relative changes over time in TEER after exposing HCE models reconstructed in CVM chambers to test chemicals. This new test method is called the Vitrigel eye irritancy test (Vitrigel-EIT) method. Thus far, thirty chemicals have been classified successfully as irritants or non-irritants without false negatives using the Vitrigel-EIT method (Yamaguchi et al., 2013).

In association with the International Collaboration on Alternative Test Methods (ICATM), an international validation management team (VMT) was organized to validate the reliability and relevance of this test method, and a validation study was performed with the cooperation of three Japanese laboratories. Testing was conducted using a protocol developed by Yamaguchi and Takezawa using test chemicals distributed via the Japanese Center for the Validation of Alternative methods (JaCVAM). Descriptive statistics are used to summarize the data obtained from the testing. The aim of this trial is to validate the capability of the Vitrigel-EIT method as well as to assess transferability and between-laboratory reproducibility in preparation for incorporating this test into the screening of test chemicals for the eye irritation potential in accordance with the United Nations' Globally Harmonized System of Classification and Labelling of Chemicals (GHS) categories (United Nations, 2013). This multi-phase validation study of the Vitrigel-EIT method was undertaken in accordance with:

- i) the principles and criteria documented in the Organization for Economic Co-operation and Development (OECD) No. 34 Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment (OECD, 2005),
- ii) the Modular Approach to Validation (Hartung et al., 2004), and
- iii) the concepts discussed in The Principles of Good Laboratory Practice: Application to In Vitro Toxicological Studies (Cooper-Hannan et al., 1999).

Testing performed as part of a validation study should ideally be performed in accordance with GLP (OECD, 1998) and necessarily include, without being limited to, the use of standard operating procedures (SOP) and adequate recording of data as well as suitable reporting of results and archival record keeping.

The “modular approach to validation” is a general conceptual framework for documenting the validation of a test method (Hartung et al., 2004; OECD, 2005). In this approach, the information needed to support the validity of the method is organized into modules, as follows.

- Module 1: Test Definition
- Module 2: Within-laboratory repeatability and reproducibility
- Module 3: Between-laboratory transferability
- Module 4: Between-laboratory reproducibility
- Module 5: Predictive capacity
- Module 6: Applicability domain
- Module 7: Performance standards

The modular approach introduced by Hartung et al. (2004) allows the use of datasets from a variety of sources, and this principle was applied in our assessment of the scientific validity of the Vitrigel-EIT method. As a specific goal, this validation study was designed to clarify whether or not the Vitrigel-EIT test method is a useful alternative to the Draize test method in a bottom-up approach for distinguishing chemical substance.

3 Methods

3.1 Study Plan

3.1.1 Purpose

This validation study is designed to assess the reliability (within- and between-laboratory reproducibility) and relevance (predictive capacity) of the Vitrigel-EIT method using a challenging set of test chemicals for which high quality in vitro and in vivo data are available. The test chemicals are to include each type of UN GHS category as classified by in vivo data and predictive capacity is to be assessed primarily in accordance with UN GHS classification in a bottom-up approach (Scott, 2010).

3.1.2 Organization

Members of the VMT contribute their collective expertise in the underlying science and scientific design, management, and evaluation of validation studies. The management structure for this validation study of the Vitrigel-EIT method is shown in Fig. 1.

The VMT is responsible for overseeing the conduct of the validation study, including signing and

dating the approval of all protocols, study plans, reports, and amendments.

The members of the VMT as well as their respective roles and expertise for this validation study of the Vitrigel-EIT method are shown in Table 1 and Fig. 1.

Table 1. The Vitrigel-EIT Validation Management Team

Name	Role and expertise	Affiliation
Hajime Kojima	Trial coordinator, Chemical management and Quality assurance	Japanese Center for the Validation of Alternative Methods (JaCVAM), National Institute of Health Sciences (NIHS)
Toshiaki Takezawa Hiroyuki Yamaguchi	Developer of this assay and expertise underlying science as the lead laboratory	Institute of Agrobiological Sciences (NIAS), National Agriculture and Food Research Organization (NARO)
Takashi Sozu	Data analysis and biostatistics dossier	Tokyo Univ. of Science
Liaison members		
Nicole Kleinstreuer	Validation study expertise	National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)/ Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), USA
Michael-Wilhelm SCHAEFFER	Validation study expertise	European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Italy
Lim, Chae-Hyung	Validation study expertise	Korean Center for the Validation of Alternative Methods (KoCVAM), Korea
Wannhsin Chen	Validation study expertise	Industrial Technology Research Institute, (ITRI), Taiwan




Fig.1. Management Structure for the Vitrigel-EIT validation study

3.1.2.1 Trial coordinator

A trial coordinator was appointed by the VMT to be responsible for preparing draft study plans, a study protocol, and a list of test chemicals as well as to convene ad hoc VMT meetings for review and finalization of the study plan, the study protocol, and the test chemical list. The trial coordinator was also responsible for other administrative duties related to the validation study.

3.1.2.2 Chemical management group

The chemical management group comprised at least one member selected from the VMT and was responsible for preparing a list of test chemicals as well as conferring with the trial coordinator to finalize the list test chemicals to be used in the validation study. It also prepared and distributed non-coded or coded lists of test chemicals to chemical distributors.

3.1.2.3 Data analysis group

The data analysis group comprised at least one member selected from the VMT and was responsible for providing an objective analysis of data obtained in this validation study as well as for performing statistical processing of the data.

3.1.2.4 Record management group

The record management group comprised at least one member selected from the VMT as well as a representative of the lead laboratory was responsible for preparing the test protocol, the test chemical preparation sheets, blank data sheets, and any other necessary materials as well as for distributing these materials to the participating laboratories. It also collected the completed forms and data sheets after testing, reviewed the records for errors and omissions, and requested correction as necessary.

3.1.2.5 Lead laboratory

The lead laboratory represents the test developers and was responsible for providing the test method protocol as well as test chemical preparation record forms, blank data sheets, and all other necessary

documentation. The lead laboratory was also responsible for providing revised versions of the protocol as necessary throughout the entire validation study. The VMT consulted with both the lead laboratory and the other participating laboratories on technical issues.

3.1.2.6 *Participating laboratories*

The following three laboratories in Japan participated in the testing of substances using the Vitrigel-EIT method. The name of the on-site study director is given in parenthesis.

Lab A: Hatano Research Institute, Food and Drug Safety Center (FDSC), Hatano, Kanagawa (Mika Watanabe)

Lab B: Bozo Research Center (BRC), Tokyo (Takayuki Fukuda)

Lab C: Daicel Corporation (Daicel), Himeji, Hyogo (Kunihiko Yamashita)

All three of these laboratories were naïve and were selected for participation by the VMT after practical training that provided a good indication of the robustness of the test method.

A coordinator from each of these three laboratories participated in VMT activities as observers and was responsible for ensuring that the tests were performed in accordance with the study protocol as well as for filling out and submitting all necessary records and forms upon completion of testing.

3.1.3 Study design

This validation study of the Vitrigel-EIT method was carried out in four phases in accordance with the study plan as described in Appendix 8.1 and summarized in Table 2.

Table 2. Overview of the Vitrigel-EIT validation study

Phase	The number of the test chemicals	The number of the repetitions	Examination
0	5	3	Within- laboratory transferability
I	10	3	Between- laboratory transferability & Within- and between- laboratory reproducibility
II	10	1	Between- laboratory reproducibility
III	36	1	Between- laboratory reproducibility and predictability

3.1.3.1 *Training of personnel at the participating laboratories*

A technical transfer workshop to explain the principles of and protocol for validation of the Vitrigel-EIT method was held May 22 and 23, 2013, with personnel from all three laboratories in attendance. Instructors from the lead laboratory explained the test method while demonstrating the protocol. All personnel in attendance performed the assay themselves, using saline, ethanol and silicic acid anhydrate. After the workshop, the coordinators from each participating laboratory agreed to purchase the cell line from RIKEN BioResource Center (Tsukuba, Japan) and to sign a memorandum pertaining to borrowing the TEER recorder.

3.1.3.2 Phase 0

Phase 0 was designed to assess between-laboratory transferability by testing five non-coded test chemicals using protocol ver. 1.30e. Each test chemical was determined to be either positive or negative by obtaining consistent results from each of three runs.

3.1.3.2 Phase I

Phase I was designed to assess within and between-laboratory reproducibility by testing ten coded test chemicals using protocol ver. 1.51e. Each test chemical was determined to be either positive or negative by obtaining consistent results from each of three runs in three different sets.

3.1.3.3 Phase II

The original plan was split into two parts: A and B. Phase IIA was designed to assess the between-laboratory reproducibility of ten coded test chemicals using protocol ver. 1.61e, after which Phase IIB was to validate an additional thirty coded test chemicals using the same protocol. Phase IIB was canceled when the results of Phase IIA led to a decision to undertake a major revision of protocol ver. 1.61e. Consequently, Phase IIA was renamed Phase II, and the planned Phase IIB was incorporated into a newly designed Phase III using the protocol ver. 1.71e.

3.1.3.4 Phase III

Phase III was designed to assess the between-laboratory reproducibility and predictive capacity of the Vitrigel-EIT method for thirty-six coded test chemicals using protocol ver. 1.71e. Each test chemical was determined to be either positive or negative based on obtaining consistent results from each of three runs in one set.

3.1.4 Success criteria

Success criteria for within and between-laboratory reproducibility was 80%. The predictive capacity was assessed using thirty-six coded test chemicals. The results of statistical analysis were used to determine the preliminary design for validation study as well as automatization of the test leading to an increased dataset.

Issues related to the applicability domain were discussed by the VMT decision during assessment of between-laboratory reproducibility.

3.2 Summary of protocol

The current test protocol is ver. 1.80e, which was designed per Yamaguchi et al., 2013, 2015 and is shown in Appendix 8.2. The data sheet format is shown in Appendix 8.3.

3.2.1 Culturing HCE-T cells

An SV40-immortalized HCE cell strain (HCE-T cells, RCB no. 2280) was obtained from RIKEN BioResource Center (Tsukuba, Japan). The cells were maintained in a culture medium comprising a 1:1 mixture of Dulbecco's modified eagle medium and nutrient mixture F-12 supplemented with 5% heat-inactivated fetal bovine serum, 5 µg/mL recombinant human insulin, 10 ng/mL recombinant

human epidermal growth factor, 0.5% dimethyl sulfoxide, 100 units/mL penicillin and 100 µg/mL streptomycin (Araki-Sasaki et al., 1995; Yamasaki et al., 2009). Cells were grown at 37°C in a humidified atmosphere of 5% CO₂.

3.2.2 Preparation of collagen vitrigel membrane chambers

A collagen xerogel membrane chamber (ad-MED Vitrigel™) was purchased from Kanto Chemical Co., Inc. (Tokyo, Japan). The collagen xerogel membrane chamber was set in the well of a 12-well plate. Then, the collagen xerogel membrane was immersed in the culture medium by pouring 1.5 mL outside and 0.5 mL inside the chamber in the well for 10 min to convert the xerogel into vitrigel immediately before use.

3.2.3 Reconstruction of a human corneal epithelium model

The culture medium outside the chamber in the well of a 12-well plate was replaced with 1.5 mL of fresh medium. The medium inside the chamber was removed and 0.5 mL of a cell suspension in a culture medium at a density of 1.2×10^5 cells/mL was poured onto the CVM in the chamber and cultured for 2 days at 37°C. Subsequently, the cells were cultured for 4 days at the air–liquid interface to fabricate a HCE model after removing the inside medium and changing the outside medium outside of the chamber. The medium outside the chamber was changed on the third day of culturing at the air–liquid interface.

3.2.4 Mode of action in vivo

Time-dependent relative changes of TEER values after exposing chemicals to in vitro human corneal epithelial models are considered to be an excellent indicator for extrapolating the destructive activity of the chemicals against the barrier function of human corneal epithelium in vivo. For this reason, the TEER assay is a simple and suitable method for evaluating corneal irritancy and permeability quantitatively and continuously (Uematsu et al., 2007). Therefore, it is important to develop an assay system that can facilitate not only the reconstruction of human corneal epithelial model but also the TEER measurement and the chemical exposure.

Our preliminary results based on the testing of four chemicals demonstrated a correlation between irritancy potential and changes in TEER. We found that non-irritants caused virtually no change in TEER, moderate irritants caused only a gradual decrease of limited magnitude in TEER, and strong irritants caused a rapid decrease of significant magnitude in TEER (Takezawa et al. 2011a). During further testing of 30 chemicals, we consistently observed these three patterns, which we were able to express mathematically using three parameters, namely, time lag, intensity, and plateau (Yamaguchi et al. 2013).

In this study, we aimed to develop such an ideal assay method utilizing HCE-T cells and the collagen vitrigel membrane chamber useful for TEER measurement.

3.2.5 Calculation of TEER values for HCE models

The electrical resistance of a HCE model in a CVM chamber (R_{model}) and of a blank CVM chamber

(R_{blank}) were measured using the TEER recorder shown in Fig. 2. The TEER value was calculated as follows:

$$\text{TEER} = (R_{\text{model}} - R_{\text{blank}}) \times \text{effective surface area (1.0 cm}^2\text{)}$$




Fig.2. Schematic illustrations on the TEER measurement electrodes for HCE model and gross observation of TEER recorder system.

The electrode unit (A), the electrode unit applied for the culture media via HCE model (B) and the TEER recorder system (C).

3.2.6 Exposure to test chemicals

A solution of test chemical was prepared in a culture medium at a concentration of 2.5% (weight/volume), which is considered appropriate for measuring TEER values without undue influence from the electrical resistance of the test chemical itself. Test chemicals were manually mixed in the medium until the test chemical dissolves or for a maximum of one minute. If the test chemical does not dissolve readily, try using the following techniques in the following order to dissolve it: a) mix mechanically for a maximum of one minute using a vortex mixer, b) sonication for a maximum of 20 minutes, or c) heating to a maximum temperature of 70°C. After trying each technique, the temperature of each test chemical solution was checked. Test chemical solution that is well dissolved or homogeneously dispersed, was moved to the next step. For test chemicals that proved to be insoluble or immiscible using the above technique, a test chemical solution was prepared as a homogeneous suspension by mixing the test chemical in the medium by vortex for up to 1 minute immediately before use (Fig.3). The pH level of each 2.5% test chemical solution was measured using universal pH test paper from ADVANTEC (Tokyo, Japan).

The HCE models were exposed to a test chemical on day 6, as follows: First, 500 μL of culture medium was poured in the chamber and the TEER recorder was used to obtain a pre-exposure R_{model} value for each model. Next, the medium inside the chamber was replaced with 500 μL of test chemical solution and R_{model} values were measured at intervals of 10 seconds for a period of 3 min after exposure to the test solution. Here, it is essential to obtain the reproducible data that the measurement is started within 2 to 5 seconds after adding the test chemicals. Because the liquid condition around the electrode is often unstable within 2 seconds after exposing the test chemical solution. Also, the HCE model has already been influenced with the test chemicals over 5 seconds. Three runs were made

for each test chemical and a new HCE model was used in each. Test chemical exposure was conducted at an ambient temperature of $28\pm 2^\circ\text{C}$. The ambient temperature of $28\pm 2^\circ\text{C}$ for the HCE model was achieved by regulating the temperature of the 12-well plate using a hot plate, a water bath or an air conditioner. Here, it is important to confirm that the actual temperature of culture medium is $28\pm 2^\circ\text{C}$.




Fig.3. Preparation of test chemical solution per the revised protocol

3.2.7 Calculating eye irritancy of test chemicals

The TEER values for each test chemical were measured during the three runs and then copied to a data sheet, where eye irritancy was calculated automatically. The mean TEER values for all three tests were plotted on a time line and a profile of TEER values (dP/dT) was automatically analyzed for three parameters: time lag (t_1), intensity ($-(P_2 - P_1)/(t_2 - t_1)$), and plateau level ($100 - P_2$). Time lag (t_1) is defined as the maximum time at which a profile was maintained at $0 \geq dP/dT > -0.03\%/second$. The starting time of plateau level (t_2) after the profile was maintained at $dP/dT \leq -0.03\%/second$ for a particular period of time was defined as the initial time at which the profile was maintained at $0 \geq dP(P_3 - P_2)/dT(t_3 - t_2) > -0.03\%/s$. The time (t_3) is represented in the equation ($t_3 = t_2 + 30$ seconds) because the plateau level was evaluated by the profile for 30 seconds. P_1 , P_2 , and P_3 are the percentages against the initial TEER value at t_1 , t_2 , and t_3 after exposure to the test chemical, as shown in Fig. 4. A score for each index was calculated using the above formula. Subsequently, the eye irritation potential of test chemicals was determined to be either irritant or non-irritant, in accordance with the criteria shown in Table 3.




Fig. 4. Schematic illustration showing an analysis of a TEER profile after exposure of a model to a test chemical.

t_1 represents time lag, and t_2 represents the start of the plateau level. t_3 is defined as $t_2 + 30$ s.

P_1 , P_2 , and P_3 indicated a percentage relative to the initial TEER value at t_1 , t_2 , and t_3 , respectively.

Table 3. Eye irritancy criteria.

Criteria	Prediction
Time lag ≤ 180 or Intensity ≥ 0.05 or Plateau level > 5.0	Irritant (I)
Time lag > 180 and Intensity < 0.05 and Plateau level ≤ 5.0	Non-irritant (NI)

3.2.8 Correlation with the UN GHS classification

The correlation with the UN GHS classification of test chemicals was estimated by calculating sensitivity, specificity, and accuracy, as follows.

$$\text{Sensitivity (\%)} = A / (A + B) \times 100$$

$$\text{Specificity (\%)} = D / (C + D) \times 100$$

$$\text{Accuracy (\%)} = (A + D) / (A + B + C + D) \times 100$$

A is the number of test chemicals classified as irritants by both the traditional UN GHS classification and the Vitrigel-EIT method. B is the number of test chemicals classified as irritants by the traditional UN GHS classification and as non-irritants by the Vitrigel-EIT method. C is the number of test chemicals classified as non-irritants by the traditional UN GHS classification and as irritants by the Vitrigel-EIT method. D is the number of test chemicals classified as non-irritants by both the traditional UN GHS classification and the Vitrigel-EIT method.

3.2.9 Commercial availability and/or intellectual property rights to the test method and its components

All components and reagents using in the test method are commercially available. HCE-T cells can be globally distributed from RIKEN BioResource Center. The Vitrigel-EIT method is available without any restriction by its intellectual property rights. Vitrigel is registered trade mark of National Agriculture and Food Research Organization (Tsukuba, Japan).

3.3 Test chemicals

3.3.1 Selection and distribution of test chemicals

The test chemicals were selected to ensure that a diverse range of substances were represented, and aspects such as eye-irritant level per UN GHS categories, physical state, chemical class, and incidence of eye lesions were considered. Preference was given to test chemicals for which high-quality in vivo data is available, especially when the data included results from individual animals. The list includes test chemicals that were previously used in the 3-dimensional corneal model (such as EpiOcular) validation studies by EURL-ECVAM (ECETOC, 1998), the Short Time Exposure test validation study by JaCVAM and independent peer review (ICCVAM, 2010, 2013), and the OptiSafe™ evaluation study by NICEATM. According to Barroso's paper (2017), classification of in vivo was revised after the validation studies and no clear results are described at "unknown" in Tables.

All the test chemicals selected for this validation study are available commercially, were selected by the chemical management group, and approved by the VMT. All the test chemicals used in Phases I, II, and III were coded, and their names were provided only after completion of the study. A total of 42 substances were tested by all three laboratories.

3.3.2 Test chemicals for Phases 0, I, II, and III

3.3.2.1 Test chemicals for Phase 0

Five test chemicals were selected by the VMT for use in validating between-laboratory transferability during Phase 0, as shown in Table 4. The five non-coded test chemicals were delivered to each participating laboratory by the VMT.

Table 4. List of test chemicals selected for Phase 0

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS*
Positive control	Ethanol	64-17-5	Liquid	-0.31	7	2A	Category 2A or higher
0-2	2-Propanol	67-63-0	Liquid	0.78	0.05	7	Category 2A
0-3	Glycerol	56-81-5	Liquid	1.26	-1.76	7	No Category
0-4	n-Hexanol	111-27-3	Liquid	0.82	2.03	7	Category 2A
0-5	Silicon dioxide n-hydrate	7699-41-4	Solid	1.58	-	7	No Category?
0-1	Benzalkonium chloride	8001-54-5	Solid	0.99	1.68	7	Unknown

*: Barroso, et al. (2017)

3.3.2.2 Test chemicals for Phase I

Ten test chemicals were selected by the VMT for use in validating within- and between-laboratory reproducibility during Phase I, as shown in Table 5. The ten test chemicals comprised five irritants and five non-irritants, five of which were solid and five of which were liquid, as shown in Table 5. To assess the within-laboratory reproducibility, the VMT selected ten test chemicals in Phase I. The VMT decided this scale based on our biostatistician's opinion about the statistical validity of the

number of test chemicals used for the ECVAM validation study for skin sensitization. A detailed background is addressed at appendix 8-12. The ten test chemicals were coded and delivered in three sets to each participating laboratory by the VMT. Refer to the chemical selection report in Appendix 8.4 for code numbers.

Table 5. List of test chemicals selected for Phase I

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS*
1-1	Imidazole	288-32-4	Solid	1.03	-0.08	9	Category 1
1-2	Cyclohexanol	108-93-0	Liquid	0.96	1.23	7	
1-3	3,3-Dithiodipropionic acid	1119-62-6	Solid	1.45	-0.15	4	Category 2A or 2B
1-4	Acetone	67-64-1	Liquid	0.79	-0.24	7	
1-5	3-Chloropropionitrile	542-76-7	Liquid	1.16	0.18	5	
1-6	Ammonium nitrate	6484-52-2	Solid	1.72	-	8	No Category
1-7	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7	
1-9	3-Methoxy-1,2-propanediol	623-39-2	Liquid	1.11	-1.13	7	
1-10	Gluconolactone	90-80-2	Solid	1.61	-2.48	6	Unknown
1-8	Toluene	108-88-3	Liquid	0.87	2.73	7	

*: Barroso, et al. (2017)

3.3.2.3 Test chemicals for Phase II

Ten test chemicals were selected by the VMT for use in validating between-laboratory reproducibility during Phase II, as shown in Table 6. The ten test chemicals comprised four classified UN GHS Category 1, three classified UN GHS Category 2A or 2B, and three classified UN GHS No Category, five of which were solids and five of which were liquid, as listed in Table 6. The ten test chemicals were coded and delivered in one set to each participating laboratory by the VMT. Refer to the chemical selection report in Appendix 8.4 for code numbers.

Table 6. List of test chemicals selected for Phase II

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS*
2-1	Imidazole	288-32-4	Solid	1.03	-0.08	9	Category 1
2-2	Cyclohexanol	108-93-0	Liquid	0.96	1.23	7	
2-4	Sodium salicylate	54-21-7	Solid	0.32	0.42	7	

2-5	Cyclopentanol	96-41-3	Liquid	0.95	2.41	7	Category 2A or 2B
2-6	2-Methyl-1-pentanol	105-30-6	Liquid	0.83	1.76	7	
2-8	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7	No Category
2-10	Gluconolactone	90-80-2	Solid	1.61	-2.48	6	Unknown
2-3	Sodium dodecyl sulfate	151-21-3	Solid	0.40	1.60	7	
2-7	α -Hexylcinnamaldehyde	101-86-0	Liquid	0.95	5.12	7	
2-9	Toluene	108-88-3	Liquid	0.87	2.73	7	

*: Barroso, et al. (2017)

3.3.2.4 Test chemicals for Phase III

Thirty-six test chemicals were selected by the VMT for use in validating between-laboratory reproducibility and predictive capacity during Phase III, as shown in Table 7. The number of chemicals, total 36 chemicals, was decided in consideration of Kanto Chemical's ability to supply the CVM chambers as well as the participating laboratories' testing capacity. All test chemicals were selected to ensure that a diverse range of substances were represented, and aspects such as eye-irritant level per UN GHS categories, physical state, chemical class, and incidence of eye lesions were considered. Preference was given to test chemicals for which high-quality in vivo data is available, especially when the data included results from individual animals. The number of test chemicals in each GHS classification is shown in Table 8. The number of solid and liquid test chemicals is shown in Table 9. The twenty-seven test chemicals were coded and delivered in one set to each participating laboratory by the VMT. Refer to the chemical selection report in Appendix 8.4 for code numbers. The chemical master at Lab C revealed the name of test chemical No. 3-16, sodium chloroacetate, which was subsequently eliminated from the list and cyclopentanol was delivered by the VMT as an alternative.

Table 7. List of test chemicals selected for Phase III

No.	Test chemical	CASRN	State	Density (g/cm ³)	logP	pH	GHS*
3-2	2-Benzyl-4-chlorophenol	120-32-1	Solid	1.19	3.60	7	Category 1
3-4	Captan	133-06-2	Solid	1.74	2.80	7	
3-6	Butanol	71-36-3	Liquid	0.81	0.88	8	
3-7	3-(2-Aminoethylamino) propyl]trimethoxysilane	1760-24-3	Liquid	1.01	-1.00	10	
3-9	m-Phenylenediamine	108-45-2	Solid	1.14	-0.33	8	
3-10	Tetraethylene glycol	17831-71-9	Liquid	1.13	1.26	7	
3-30	Imidazole	288-32-4	Solid	1.03	-0.08	9	
3-32	Sodium salicylate	54-21-7	Solid	0.32	0.42	7	Category
3-11	gamma-Butyrolactone	96-48-0	Liquid	1.13	-0.64	7	
3-12	Methyl acetate	79-20-9	Liquid	0.93	0.18	7	ory

3-14	2,6-Dichlorobenzoyl chloride	4659-45-4	Liquid	1.47	2.54	3	2A or 2B
3-15	Dibenzyl phosphate	1623-08-1	Solid	1.46	1.71	3	
3-17	1-(2-Propoxy-1-methylethoxy)-2-propanol	29911-27-1	Liquid	0.94	1.14	7	
3-18	Camphene	79-92-5	Solid	0.84	1.94	7	
3-19	Ethyl-2-methylacetoacetate	609-14-3	Liquid	1.00	0.78	7	
3-20	Propylene glycol propyl ether	1569-01-3	Liquid	0.89	0.56	8	
3-31	2-Methyl-1-pentanol	105-30-6	Liquid	0.83	1.76	7	
3-37	Cyclopentanol	96-41-3	Liquid	0.95	2.41	7	
3-21	Methyl amyl ketone	110-43-0	Liquid	0.82	1.98	7	No Cate gory
3-22	2-(n-Dodecylthio)ethanol	1462-55-1	Liquid	0.91	-	7	
3-23	iso-Octylthioglycolate	25103-09-7	Liquid	0.97	4.36	7	
3-24	2,4-Difluoronitrobenzene	446-35-5	Liquid	1.46	-1.18	7	
3-26	2,4-Pentanediol	625-69-4	Liquid	0.96	0.35	8	
3-27	iso-Octyl acrylate	29590-42-9	Liquid	0.88	4.61	7	
3-29	Potassium tetrafluoroborate	14075-53-7	Solid	2.51	-	7	
3-34	n,n-Dimethylguanidine sulfate	598-65-2	Solid	-	-	7	
3-36	Gluconolactone	90-80-2	Solid	1.61	-2.48	6	Unkw on
3-1	2,5-Dimethyl-2,5-hexanediol	110-03-2	Solid	0.90	1.19	7	
3-3	2,2-Dimethyl butanoic acid	595-37-9	Liquid	0.93	1.90	4	
3-5	Tetra-n-octylammonium bromide	14866-33-2	Solid	0.94	3.45	7	
3-8	Sodium dodecyl sulfate	151-21-3	Solid	0.40	1.60	7	
3-13	Myristyl alcohol	112-72-1	Solid	0.82	6.03	7	
3-33	α -Hexylcinnamaldehyde	101-86-0	Liquid	0.95	5.12	7	
3-25	tetra-Aminopyrimidine sulfate	5392-28-9	Solid	1.65	0.27	3	
3-28	Silicon dioxide n-hydrate	7699-41-4	Solid	1.58	-	7	
3-35	Toluene	108-88-3	Liquid	0.87	2.73	7	

*: Barroso, et al. (2017)

Table 8. Breakdown of test chemicals used in Phase III

GHS			Total
Category 1	Category 2A/2B	No Category	
8	10	9	27

*:The test chemicals classified at “unknown” were excluded.

Table 9. Breakdown of test chemicals used in Phase III per physical state

Solid	Liquid	Total
10	17	27

*:The test chemicals classified at “unknown” were excluded.

3.4 Quality assurance

All testing at the participating laboratories was conducted in accordance with the principles of Good Laboratory Practice (GLP, OECD 1998), and were well documented, including a discussion of any impact on study results. Records were kept of the maintenance of measuring instruments, the production of HCE models, and the preparation and application of test chemicals using a format prepared by the lead laboratory. The data was input using a format developed for this validation study by the lead laboratory and the biostatistician. Personnel at the participating laboratories recorded the necessary information, including the code names of each test chemical, names and date of preparation of solvents, degree of solubility or suspensibility, and concentration of the test solution. These records were sent from the participating laboratories to JaCVAM, where they were checked for validity and accuracy as well as archived.

3.5 Record collection and analysis

Data collection and analysis were performed in close collaboration with biostatisticians and the quality assurance group. Independent biostatisticians collected and organized data as shown in Appendix 8.5 using custom data collection software, and all records were checked by the quality assurance group. Any concerns at the participating laboratories over record keeping were resolved by the on-site study director and reported at VMT meetings.

At the final VMT meeting, all data was finalized and decoded by the trial coordinator, after which the biostatisticians performed a statistical analysis. Data management procedures and statistical tools were approved by the trial coordinator and the data analysis group. Any deviation found in the analysis was well documented, including a discussion of any impact on study results. Test results were evaluated for correlation with UN GHS classification based on predetermined criteria.

Predictive capacity of the Vitrigel-EIT method was evaluated using data from Phase III. First, an analysis was performed to assess predictive capacity in accordance with UN GHS classification per either a bottom-up or a top-down approach (Scott, 2010). Further analysis was then performed to reduce false negatives by limiting the scope of the applicability domain.

4 Results

All data were analyzed by biostatisticians as shown in Appendix 8.5. The quality assurance group checked all records, following the quality assurance protocol, as summarized in Appendix 8.6.

4.1 Study duration

Phase 0 was conducted from June to December 2013, using protocol ver. 1.30e.

Phase I was conducted from March to April 2014, using protocol ver. 1.51e.

Phase II was conducted from June to September 2014, using protocol ver. 1.61e.

Phase III was conducted from November 2014 to January 2015, using protocol ver. 1.71e.

VMT meetings were held during the intervals between these phases. The minutes of the VMT meetings are shown in Appendix 8.7.

4.1.1 Phase 0

Phase 0 was designed to assess between-laboratory transferability by testing five non-coded test

chemicals using protocol ver. 1.30e.

Although the results were generally good, two issues were identified: the results for glycerol obtained at BRC were inconsistent, and those for ethanol (positive control) obtained at Daicel did not meet the success criteria for between-laboratory reproducibility shown in Tables 10 and 11. With the exception of the results for glycerol obtained at BRC, the data was overall highly consistent. The results for two of the three runs of ethanol at Daicel fell below the acceptance criteria for positive control (plateau level: 20 to 30%) in Fig.5. At the 1st VMT meeting, members discussed a proposal to use benzalkonium chloride as the positive control instead of ethanol, in order to ensure clear and consistent results. Ultimately, ethanol was used as a reference control, and its range was modified to 15–30% at plateau level. This exact range was to be finalized based on the results of Phase I.

The VMT requested additional testing at BRC and Daicel using a revised protocol, ver. 1.40e. After confirming the results of the additional testing (data not shown), all VMT members agreed to proceed with Phase I. The following key issues were addressed by revising the protocol to ver. 1.51e prior to the start of Phase I.

- Success criteria for the reference control: Range at plateau level of 10–30%
- Ambient temperature during TEER measurement: 18–30°C
- Time from start of exposure to start of measurement: within 2 seconds

Table 10-1. Data for Phase 0, Trial 1

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	20 (I)	0.13 (I)	23 (I)	I	0 (I)	0.11 (I)	21 (I)	I	10 (I)	0.09 (I)	18 (NI)	N
0-1	Benzalkonium chloride	0 (I)	0.32 (I)	58 (I)	I	0 (I)	0.30 (I)	54 (I)	I	0 (I)	0.21 (I)	37 (I)	I
0-2	2-Propanol	10 (I)	0.17 (I)	32 (I)	I	0 (I)	0.16 (I)	29 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.31 (I)	22 (I)	I	10 (I)	0.12 (I)	4 (NI)	I	0 (I)	0.25 (I)	13 (I)	I
0-4	n-Hexanol	0 (I)	0.21 (I)	38 (I)	I	30 (I)	0.14 (I)	23 (I)	I	10 (I)	0.15 (I)	27 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI

Table 10-2. Data for Phase 0, Trial 2

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	10 (I)	0.12 (I)	22 (I)	I	0 (I)	0.12 (I)	21 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-1	Benzalkonium chloride	0 (I)	0.32 (I)	57 (I)	I	0 (I)	0.30 (I)	54 (I)	I	0 (I)	0.33 (I)	60 (I)	I
0-2	2-Propanol	0 (I)	0.13 (I)	24 (I)	I	0 (I)	0.18 (I)	32 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.31 (I)	12 (I)	I	190 (NI)	-0.10 (NI)	2 (NI)	NI	0 (I)	0.21 (I)	12 (I)	I
0-4	n-Hexanol	10 (I)	0.15 (I)	28 (I)	I	0 (I)	0.21 (I)	37 (I)	I	40 (I)	0.11 (I)	19 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	0.00 (NI)	0 (NI)	NI

Table 10-3. Data for Phase 0, Trial 3

No.	Test chemical	FDSC			BRC			Daicel					
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.10 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
	Positive control (ethanol)	20 (I)	0.12 (I)	22 (I)	I	0 (I)	0.14 (I)	21 (I)	I	10 (I)	0.10 (I)	19 (NI)	NI
0-1	Benzalkonium chloride	0 (I)	0.34 (I)	62 (I)	I	0 (I)	0.29 (I)	52 (I)	I	0 (I)	0.30 (I)	55 (I)	I
0-2	2-Propanol	10 (I)	0.15 (I)	29 (I)	I	0 (I)	0.16 (I)	29 (I)	I	10 (I)	0.13 (I)	24 (I)	I
0-3	Glycerol	0 (I)	0.30 (I)	18 (I)	I	0 (I)	0.41 (I)	16 (I)	I	0 (I)	0.19 (I)	13 (I)	I
0-4	n-Hexanol	0 (I)	0.22 (I)	39 (I)	I	0 (I)	0.16 (I)	28 (I)	I	20 (I)	0.15 (I)	27 (I)	I
0-5	Silicon dioxide n-hydrate	190 (NI)	-0.01 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI

7

8


9

Table 11. Combined results for Phase 0

No.	Test chemical	FDSC			BRC			Daicel		
		1	2	3	1	2	3	1	2	3
	Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
	Positive control (ethanol)	Pass	Pass	Pass	Pass	Pass	Pass	NG	Pass	NG
0-1	Benzalkonium chloride	I	I	I	I	I	I	I	I	I
0-2	2-Propanol	I	I	I	I	I	I	I	I	I
0-3	Glycerol	I	I	I	I	NI	I	I	I	I
0-4	n-Hexanol	I	I	I	I	I	I	I	I	I
0-5	Silicon dioxide n-hydrate	NI	NI	NI	NI	NI	NI	NI	NI	NI

10

11



12

13 Fig. 5. Distribution of the three trials of Phase 0

14

15 4.1.2 Phase I

16 Phase I was designed to assess within and between-laboratory reproducibility by testing ten coded test
 17 chemicals using protocol ver. 1.51e.

18 The results for two of nine runs of the reference control (ethanol) at FDSC did not initially meet the
 19 success criteria, but were successfully retested, as shown in Tables 12 and 13. Analysis of Phase 0 and
 20 Phase I results as well as concerns for quality assurance of the HCE models led the VMT to include
 21 success criteria for the reference control in the next version of the test protocol. Consequently, the
 22 VMT recommended that the range for the reference control should be revised, so expanded success
 23 criteria for the positive and reference controls were developed by the lead laboratory. Furthermore,
 24 the results for test chemical No. 1-7, n,n-dimethyl guanidine sulfate, and No. 1-10, gluconolactone at
 25 FDSC as well as for test chemical No. 1-8, toluene, at Daicel failed to satisfy the success criteria for
 26 the within-laboratory reproducibility, as shown in Tables 12 and 14. All results at BRC met the success
 27 criteria. Thus, the within-laboratory reproducibility was 80% at FDSC, 90% at Daicel, and 100% at
 28 BRC, which was sufficient to satisfy the success criteria of 80% as stated in the study plan. Although
 29 the results for No. 1-1, imidazole, and No. 1-8, toluene, were somewhat inconsistent, the data showed
 30 a between-laboratory reproducibility of 80%, which met the acceptance criteria of 80% as stated in
 31 the study plan. The following key issues were addressed by revising the protocol to ver. 1.61e prior to
 32 the start of Phase II.

- 33 • Revised the term “room temperature” to read “ambient temperature for the experiment,”
 34 because control of ambient temperature is necessary.
- 35 • Included success criteria for the reference control and changed the phrase “Plateau level is
 36 between 10% and 30%, inclusive” to “Plateau level is between 10% and 40%, inclusive”.
- 37 • Change the ambient temperature for TEER measurement from “between 18 and 30°C” to
 38 “between 22 and 30°C,” because temperature of the HCE model can affect TEER.
- 39 • Changed the description of the procedure for preparing test chemical solutions
 40 Old: If the test chemical has not been dissolved, try to dissolve it by the mechanical mixture
 41 for a maximum 1-minute period using a vortex, by the sonication for a maximum 20-minute
 42 period, or by the heating to 70°.

43 New: If the test chemical does not dissolve readily, try one of the following techniques: a) mix
44 mechanically for a maximum of one minute using a vortex mixer, b) sonication for a
45 maximum of 20 minutes, or c) heating to a maximum temperature of 70°C.

46 This was done, because some personnel at the participating laboratories misunderstood the
47 procedure during Phase 1 and thought that all three of these techniques should be performed.
48 Also, the term “vortex” was corrected to “vortex mixer.”

49 • Added a precaution to seal the 15-mL tube tightly during testing to prevent volatilization of
50 the test chemical solutions, as follows: “To prevent volatilization of test chemical solutions,
51 the 15-mL tube should be sealed tightly after weighing test chemicals, except when adding
52 culture medium and sampling the 2.5% test chemical solution.”

53 • Added instructions to reject and retest any result in which there is a significant discrepancy
54 between the initial TEER value and the TEER value measured at 0 seconds, which would
55 indicate some technical issue, such as electrical noise or improper use of electrode, as follows:
56 “If there is a discrepancy of $40 \Omega \cdot \text{cm}^2$ or more between the initial TEER value and the TEER
57 value measured at 0 seconds, reject the test results and retest using another HCE model.”

Table 12-1. Data for Phase I, Trial 1

No.	Test chemical	FDSC			BRC			Daicel					
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.35 (I)	64 (I)	I	0 (I)	0.39 (I)	51 (I)	I	0 (I)	0.35 (I)	64 (I)	I
	Reference control	20 (I)	0.09 (I)	16 (I)	I	0 (I)	0.18 (I)	16 (I)	I	10 (I)	0.14 (I)	26 (I)	I
1-1	Imidazole	190 (NI)	0.00 (NI)	0 (NI)	NI	120 (I)	0.15 (I)	11 (I)	I	130 (I)	0.12 (I)	9 (I)	I
1-2	Cyclohexanol	10 (I)	0.23 (I)	42 (I)	I	0 (I)	0.21 (I)	37 (I)	I	0 (I)	0.29 (I)	51 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.06 (NI)	0 (NI)	NI
1-4	Acetone	30 (I)	0.08 (I)	15 (I)	I	10 (I)	0.07 (I)	6 (I)	I	0 (I)	0.16 (I)	28 (I)	I
1-5	3-Chloropropionitrile	10 (I)	0.18 (I)	32 (I)	I	10 (I)	0.12 (I)	22 (I)	I	20 (I)	0.22 (I)	38 (I)	I
1-6	Ammonium nitrate	0 (I)	0.77 (I)	54 (I)	I	0 (I)	1.36 (I)	27 (I)	I	0 (I)	0.79 (I)	48 (I)	I
1-7	n,n-Dimethylguanidine sulfate	0 (I)	0.40 (I)	32 (I)	I	0 (I)	0.37 (I)	7 (I)	I	0 (I)	0.44 (I)	26 (I)	I
1-8	Toluene	190 (NI)	0.01 (NI)	0 (NI)	NI	170 (I)	0.02 (NI)	1 (NI)	I	190 (NI)	0.02 (NI)	1 (NI)	NI
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI
1-10	Gluconolactone	0 (I)	0.21 (I)	11 (I)	I	0 (I)	0.34 (I)	3 (NI)	I	0 (I)	0.22 (I)	9 (I)	I

Table 12-2. Data for Phase I, Trial 2

No.	Test chemical	FDSC			BRC			Daicel					
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	0.00 (NI)	0 (NI)	NI	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.33 (I)	59 (I)	I	0 (I)	0.23 (I)	42 (I)	I	0 (I)	0.42 (I)	75 (I)	I
	Reference control	20 (I)	-	3 (NI)	NG	0 (I)	0.12 (I)	21 (I)	I	0 (I)	0.17 (I)	30 (I)	I
1-1	Imidazole	190 (NI)	-0.03 (NI)	0 (NI)	NI	160 (I)	0.13 (I)	4 (NI)	I	140 (I)	0.11 (I)	7 (I)	I
1-2	Cyclohexanol	30 (I)	0.16 (I)	25 (I)	I	0 (I)	0.40 (I)	48 (I)	I	0 (I)	0.34 (I)	51 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.06 (NI)	0 (NI)	NI	190 (NI)	-0.07 (NI)	0 (NI)	NI	190 (NI)	-0.05 (NI)	0 (NI)	NI
1-4	Acetone	10 (I)	0.04 (NI)	10 (I)	I	0 (I)	0.12 (I)	21 (I)	I	0 (I)	0.17 (I)	30 (I)	I
1-5	3-Chloropropionitrile	90 (I)	0.19 (I)	20 (I)	I	10 (I)	0.20 (I)	36 (I)	I	10 (I)	0.21 (I)	39 (I)	I
1-6	Ammonium nitrate	0 (I)	0.69 (I)	21 (I)	I	0 (I)	0.67 (I)	27 (I)	I	0 (I)	1.05 (I)	52 (I)	I
1-7	n,n-Dimethylguanidine sulfate	190 (NI)	-0.05 (NI)	2 (NI)	NI	0 (I)	0.53 (I)	21 (I)	I	0 (I)	0.54 (I)	27 (I)	I
1-8	Toluene	190 (NI)	-0.01 (NI)	0 (NI)	NI	150 (I)	0.02 (NI)	1 (NI)	I	190 (NI)	0.00 (NI)	0 (NI)	NI
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.05 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.11 (NI)	0 (NI)	NI
1-10	Gluconolactone	190 (NI)	-0.04 (NI)	0 (NI)	NI	0 (I)	0.28 (I)	8 (I)	I	10 (I)	0.18 (I)	10 (I)	I

61 Table 12-3. Data for Phase I, Trial 3

No.	Test chemical	FDSC			BRC			Daicel					
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI	190 (NI)	-0.04 (NI)	0 (NI)	NI
	Positive control	0 (I)	0.36 (I)	65 (I)	I	0 (I)	0.31 (I)	55 (I)	I	0 (I)	0.37 (I)	66 (I)	I
	Reference control	0 (I)	0.18 (I)	33 (I)	NG	0 (I)	0.12 (I)	22 (I)	I	10 (I)	0.15 (I)	27 (I)	I

1-1	Imidazole	190 (NI)	-0.01 (NI)	0 (NI)	NI	110 (I)	0.17 (I)	13 (I)	I	60 (I)	0.14 (I)	20 (I)	I
1-2	Cyclohexanol	0 (I)	0.26 (I)	46 (I)	I	0 (I)	0.27 (I)	48 (I)	I	0 (I)	0.33 (I)	59 (I)	I
1-3	3,3-Dithiodipropionic acid	190 (NI)	-0.05 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.0 (NI)	0 (NI)	NI
1-4	Acetone	10 (I)	0.10 (I)	19 (I)	I	0 (I)	0.20 (I)	36 (I)	I	0 (I)	0.18 (I)	32 (I)	I
1-5	3-Chloropropionitrile	10 (I)	0.22 (I)	39 (I)	I	20 (I)	0.12 (I)	22 (I)	I	10 (I)	0.25 (I)	44 (I)	I
1-6	Ammonium nitrate	0 (I)	0.62 (I)	37 (I)	I	0 (I)	0.25 (I)	50 (I)	I	0 (I)	0.94 (I)	47 (I)	I
1-7	n,n-Dimethylguanidine sulfate	0 (I)	0.36 (I)	25 (I)	I	0 (I)	0.45 (I)	23 (I)	I	0 (I)	0.46 (I)	27 (I)	I
1-8	Toluene	190 (NI)	-0.03 (NI)	0 (NI)	NI	80 (I)	0.05 (I)	8 (I)	I	130 (I)	0.03 (NI)	2 (I)	I
1-9	3-Methoxy-1,2-propanediol	190 (NI)	-0.09 (NI)	0 (NI)	NI	190 (NI)	-0.12 (NI)	0 (NI)	NI	190 (NI)	-0.11 (NI)	0 (NI)	NI
1-10	Gluconolactone	10 (I)	0.10 (I)	5 (I)	I	0 (I)	0.30 (I)	9 (I)	I	10 (I)	0.18 (I)	10 (I)	I
	Reference control (2)	10 (I)	0.12 (I)	22 (I)	I	-	-	-	-	-	-	-	-

63 Table 13. Combined results for Phase I control chemicals

	FDSC			BRC			Daicel		
	1	2	3	1	2	3	1	2	3
Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
Positive control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
Reference	Pass	NG	NG	Pass	Pass	Pass	Pass	Pass	Pass
Reference (2)			Pass						

64

65

66 Table 14. Combined results for Phase I test chemicals

No.	Test chemical	FDSC			BRC			Daicel		
		1	2	3	1	2	3	1	2	3
1-1	Imidazole	NI	NI	NI	I	I	I	I	I	I
1-2	Cyclohexanol	I	I	I	I	I	I	I	I	I
1-3	3,3-Dithiodipropionic acid	NI	NI	NI	NI	NI	NI	NI	NI	NI
1-4	Acetone	I	I	I	I	I	I	I	I	I
1-5	3-Chloropropionitrile	I	I	I	I	I	I	I	I	I
1-6	Ammonium nitrate	I	I	I	I	I	I	I	I	I
1-7	n,n-Dimethylguanidine sulfate	I	NI	I	I	I	I	I	I	I
1-8	Toluene	NI	NI	NI	I	I	I	NI	NI	I
1-9	3-Methoxy-1,2-propanediol	NI	NI	NI	NI	NI	NI	NI	NI	NI
1-10	Gluconolactone	I	NI	I	I	I	I	I	I	I

67

68

69

70 4.1.3 Phase II

71 Phase II was designed to assess the between-laboratory reproducibility of ten coded test chemicals
72 using protocol ver. 1.61e.

73 Results for two of the ten test chemicals failed to satisfy the success criteria for between-laboratory
74 reproducibility: No. 2-1, imidazole, and No. 2-9, toluene, as shown in Tables 15, 16, and 17. Although
75 the concordance was 80% between the three laboratories, which was sufficient to satisfy the success
76 criteria, the VMT was concerned over the failure to properly identify No. 2-1, imidazole, which is a
77 UN GHS category 1 irritant. Therefore, the VMT was unanimous in recognizing the need to clarify
78 the reason for this failure.

79 During a VMT teleconference to discuss the results of Phase II, the lead laboratory suggested that it
80 might be necessary to control the ambient temperature at which tests were conducted. The lead
81 laboratory had obtained data at the relatively high ambient temperature of 28°C. In addition, the time
82 dependent TEER profile after exposing imidazole was affected by the temperature. In case the
83 temperature below 22°C, imidazole was classified as non-irritant. All laboratories performed
84 additional testing of No. 2-1, imidazole, under the modified parameters given in Fig.6 and as shown
85 in Table 18. All laboratories correctly identified No. 2-1, imidazole, as an irritant, which suggested the
86 need for rigorous control of the ambient temperature, and led to a major revision of the protocol prior
87 to Phase III.

88 Due to this revision, the VMT recognized that Phase II data should not be combined with Phase III
89 data to assess predictive capacity and decided to undertake validation of between-laboratory
90 reproducibility and predictive capacity in Phase III using revised protocol ver. 1.71e. In consideration
91 of the capacity of the participating laboratories, the number of test chemicals for Phase III was reduced
92 from 40 in Phases IIA and IIB of the original study plan to just 36. Thus, a total of four chemicals (two
93 from UN GHS category 1, 1 from UN GHS category 2, and 1 No Category) were removed from the
94 original list of test chemicals.

95 The following key issues were addressed by revising the protocol to ver. 1.71e prior to the start of
96 Phase III.

- 97 • Having recognized the need to control ambient temperature, we replaced the instruction “Let
98 stand for 10 minutes (within 2 hours) at the ambient temperature for the experiment” to
99 “Adjust the temperature of the model to $28\pm 2^{\circ}\text{C}$.”
- 100 • Replaced all instances of the phrase “ambient temperature for the experiment” to “between
101 22 and 30°C.”
- 102 • Changed the success criteria for the reference control from “Plateau level is between 10%
103 and 30%, inclusive” to “Plateau level is 10% or more.” The upper limit for this success
104 criterion will be determined after reviewing the results of Phase III.

105

Table 15. Data for Phase II

No.	Test chemical	FDSC				BRC				Daicel			
		Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result	Time lag	Intensity	Plateau level	Result
	Negative control	190 (NI)	-0.04 (NI)	0 (NI)	NI	190 (NI)	-0.08 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
	Positive control	0 (0)	0.41 (0)	74 (0)	I	0 (0)	0.33 (0)	59 (0)	I	0 (0)	0.30 (0)	54 (0)	I
	Reference control	0 (0)	0.24 (0)	31 (0)	I	0 (0)	0.14 (0)	25 (0)	I	0 (0)	0.16 (0)	24 (0)	I
2-1	Imidazole	190 (NI)	0.00 (NI)	3 (NI)	NI	140 (0)	0.15 (0)	8 (0)	I	190 (NI)	0.00 (NI)	0 (NI)	NI
2-2	Cyclohexanol	0 (0)	0.51 (0)	51 (0)	I	0 (0)	0.32 (0)	48 (0)	I	0 (0)	0.25 (0)	38 (0)	I
2-3	Sodium dodecyl sulfate	0 (0)	0.41 (0)	74 (0)	I	0 (0)	0.32 (0)	58 (0)	I	0 (0)	0.31 (0)	56 (0)	I
2-4	Sodium salicylate	0 (0)	0.80 (0)	48 (0)	I	0 (0)	0.41 (0)	33 (0)	I	0 (0)	0.54 (0)	33 (0)	I
2-5	Cyclopentanol	0 (0)	0.28 (0)	39 (0)	I	0 (0)	0.22 (0)	40 (0)	I	0 (0)	0.17 (0)	30 (0)	I
2-6	2-Methyl-1-pentanol	0 (0)	0.30 (0)	54 (0)	I	0 (0)	0.23 (0)	35 (0)	I	10 (0)	0.14 (0)	26 (0)	I
2-7	α -Hexylcinnamaldehyde	190 (NI)	-0.03 (0)	0 (NI)	NI	190 (NI)	-0.03 (NI)	0 (NI)	NI	190 (NI)	-0.01 (NI)	0 (NI)	NI
2-8	n,n-Dimethylguanidine sulfate	0 (0)	0.83 (0)	42 (NI)	I	0 (0)	0.37 (0)	26 (0)	I	0 (0)	0.54 (0)	27 (0)	I
2-9	Toluene	60 (0)	0.06 (0)	9 (0)	I	190 (NI)	0.00 (NI)	0 (NI)	NI	190 (NI)	-0.02 (NI)	0 (NI)	NI
2-10	Gluconolactone	0 (0)	0.48 (0)	19 (0)	I	0 (0)	0.30 (0)	12 (0)	I	0 (0)	0.23 (0)	9 (0)	I

108 Table 16. Results for Phase II control chemicals

	FDSC	BRC	Daicel
Negative control	Pass	Pass	Pass
Positive control	Pass	Pass	Pass
Reference	Pass	Pass	Pass

109

110

111 Table 17. Results for Phase II test chemicals

No.	Test chemical	FDSC	BRC	Daicel
2-1	Imidazole	NI	I	NI
2-2	Cyclohexanol	I	I	I
2-3	Sodium dodecyl sulfate	I	I	I
2-4	Sodium salicylate	I	I	I
2-5	Cyclopentanol	I	I	I
2-6	2-Methyl-1-pentanol	I	I	I
2-7	α -Hexylcinnamaldehyde	NI	NI	NI
2-8	n,n-Dimethylguanidine sulfate	I	I	I
2-9	Toluene	I	NI	NI
2-10	Gluconolactone	I	I	I

112


113

114 Table 18. List of test conditions at each lab.


	Phase II study			Additional		
	Circumstances	Part measured	Temp. (°C)	Circumstances	Part measured	Temp. (°C)
FDSC	Room temp.	Room temp.	24-26	On hot plate	Medium at a well	27-28
BRC	Room temp.	Room temp.	22-25	In Water bath	Medium at a well	27.4-28.6
Daicel	Room temp.	Room temp.	22	Room temp.	Room temp.	28±2

Lead Lab	Room temp.	Medium at a well	28			
----------	------------	------------------	----	--	--	--


115



116



117



118

119

Fig.6. Additional data of Imidazole on Vitrigel-EIT phase II study

120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160

4.1.4 Phase III

During Phase III, the VMT received a question about test chemical No. 3-16, sodium chloroacetate, from the on-site study director at Daicel, who opened the MSDS due to concerns over legal compliance in handling deleterious substances. After considering the possibility of using this chemical, the VMT decided instead to delete it from the list of test chemicals, and in its place, distributed to all laboratories a new test chemical: No. 3-37, cyclopentanol. This test chemical is a UN GHS category 2B substance, just like No. 3-16, sodium chloroacetate.

There were some discrepancies in the Phase III results that can be attributed to differences the techniques used to dissolve the test chemicals. To resolve this issue, the protocol was revised to ver. 1.80e by limiting the techniques to be used to dissolve test chemicals.

Also, an additional procedure was included, which calls for the pH level of each 2.5% test chemical solution to be measured using universal pH test paper to ensure that the test chemical falls within the applicability domain.

Other procedural inconsistencies that require further study to determine whether or not standardization is necessary include the following.

- a. The time interval from the start of exposure to a test chemical until the start of TEER measurement: 4 s at FDSC, 3 s at BRC, and 2 s at Daicel
- b. Temperature of the models: 27.0–28.7°C in culture medium at FDSC, 26.4–28.0°C in a water bath at BRC, and 26.9–28.4°C in culture medium at Daicel
- c. Number of insoluble test chemicals: Of the 21 test chemical solutions prepared at FDSC, four exhibited sediment and two exhibited supernatants (Nos. 212, 216); of the 19 test chemicals prepared at BRC, 10 exhibited sediment and seven exhibited supernatants (Nos. 213, 221, 222, 223, 232, 234, and 236); and of the 17 test chemicals prepared at Daicel, seven exhibited sediment and 10 exhibited supernatant (Nos. 202, 210, 218, 219, 220, 224, 230, 231, 233, and 235).
- d. Other issues:
At Daicel, different batches of the frozen cell lines were used.
At FDSC, test chemical No. 216 was tested twice, but the data was not approved due to and inappropriate procedure.

All of the aforementioned issues were reported to the VMT, which unanimously agreed that these were minor issues that did not impact data analysis.

In Tables 19, 20, and 21, the between-laboratory reproducibility was 92% (33/36), which met the acceptance criteria of 80%. The results of a few insoluble test chemicals were inconsistent between the laboratories, including No. 3-5, tetra-N-octylammonium bromide, No. 3-14, 2,6-dichlorobenzyl chloride, and No. 3-18, camphene, and the VMT discussed the difficulties inherent in assessing these substances due to low solubility in the culture medium.

The following key issues were addressed by revising the protocol to ver. 1.80e after completion of Phase III.

- 161 • Added the term “Universal pH test paper (ADVANTEC, 07011030)” to section 3.
162 • Added a description of the applicability domain, which was determined per the results for 93
163 test chemicals.
164 • Changed the description of the procedure for preparing test chemical solution as follows.
165 Old: If the test chemical has not been dissolved, try to dissolve it by selecting an appropriate
166 technique(s) from the following; mechanical mixture for a maximum 1-minute period using
167 a vortex mixer, sonication for a maximum 20-minute period, or heating to maximum 70°C.
168 New: If the test chemical does not dissolve readily, try using the following techniques in the
169 following order to dissolve it: a) mix mechanically for a maximum of one minute using a
170 vortex mixer, b) sonication for a maximum of 20 minutes, or c) heating to a maximum
171 temperature of 70°C. After trying each technique, adjust the temperature of each test chemical
172 solution to 28±2°C and check solubility. Move to the next step of the procedure once the test
173 chemical solution is well dissolved or homogeneously dispersed.
174 • Added a precaution that techniques for dissolving test chemicals are to be set according to
175 the physiochemical properties of the test chemicals.
176

177 The Vitrigel-EIT method was developed primarily to identify ocular non-irritants in a bottom-up
178 approach. As shown in Tables 22, the Vitrigel-EIT method demonstrated an accuracy of between 66.7
179 and 70.4% (18 to 19/27), a sensitivity of between 83.3 and 88.9% (15 to 16/18), and a specificity of 33.3%
180 (3/9). These figures are lower than those of in house data obtained by the lead lab and there are too
181 many false negatives for this test method to be useful in a bottom-up approach. Substances that yielded
182 either false negative or false positive results are listed in Table 23.
183

Table 19-1. Results for Phase III control chemicals

Set	Test chemical	FDSC					BRC					DaiCel				
		Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result
1	Negative control	28.0	190 (NI)	-0.03 (NI)	0 (NI)	NI	26.4	190 (ND)	0.00 (NI)	0 (NI)	NI	28.4	190 (NI)	-0.02 (ND)	0 (NI)	NI
	Positive control	28.2	0 (I)	0.45 (I)	82 (I)	I	27.5	0 (I)	0.41 (I)	75 (I)	I	28.4	0 (I)	0.52 (I)	67 (I)	I
	Reference control	27.4	0 (I)	0.20 (I)	28 (I)	I	27.5	0 (I)	0.19 (I)	34 (I)	I	28.4	0 (I)	0.24 (I)	29 (I)	I
2	Negative control	27.2	190 (NI)	-0.03 (NI)	0 (NI)	NI	27.1	190 (ND)	-0.04 (NI)	0 (NI)	NI	27.9	190 (NI)	-0.03 (ND)	0 (NI)	NI
	Positive control	27.3	0 (I)	0.44 (I)	79 (I)	I	27.2	0 (I)	0.40 (I)	73 (I)	I	27.9	0 (I)	0.40 (I)	72 (I)	I
	Reference control	27.2	0 (I)	0.19 (I)	29 (I)	I	27.3	0 (I)	0.19 (I)	35 (I)	I	27.9	0 (I)	0.14 (I)	26 (I)	I
3	Negative control	27.6	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.6	190 (ND)	-0.04 (NI)	0 (NI)	NI					
	Positive control	27.5	0 (I)	0.36 (I)	65 (I)	I	27.7	0 (I)	0.50 (I)	90 (I)	I					
	Reference control	27.2	0 (I)	0.17 (I)	31 (I)	I	27.7	0 (I)	0.27 (I)	48 (I)	I					

* Temperature of the model at the time of exposure to the test chemical solution

Table 19-2. Results for Phase III test chemicals

No.	Test chemical	FDSC					BRC					DaiCel				
		Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result	Temp. (°C)*	Time lag	Intensity	Plateau level	Result
3-1	2,5-Dimethyl-2,5-hexanediol	27.1	10 (I)	0.14 (I)	26 (I)	I	27.6	40 (I)	0.18 (I)	26 (I)	I	27.7	60 (I)	0.17 (I)	23 (I)	I
3-2	2-Benzyl-4-chlorophenol	28.5	0 (I)	0.40 (I)	72 (I)	I	28.0	0 (I)	0.40 (I)	73 (I)	I	27.7	0 (I)	0.38 (I)	65 (I)	I
3-3	2,2-Dimethyl butanoic acid	27.6	0 (I)	0.50 (I)	60 (I)	I	27.5	50 (I)	0.23 (I)	31 (I)	I	27.7	30 (I)	0.33 (I)	49 (I)	I
3-4	Captan	27.0	190 (ND)	-0.05 (NI)	0 (NI)	NI	27.5	190 (NI)	-0.01 (ND)	0 (NI)	NI	27.9	190 (NI)	0.00 (NI)	0 (NI)	NI

3-5	Tetra-n-octylammonium bromide	27.5	60 (f)	0.17 (f)	23 (f)	I	27.5	60 (f)	0.12 (f)	17 (f)	I	27.6	190 (NI)	0.01 (NI)	0 (NI)	NI
3-6	Butanol	27.6	0 (f)	0.27 (f)	49 (f)	I	27.6	0 (f)	0.33 (f)	59 (f)	I	27.6	0 (f)	0.27 (f)	49 (f)	I
3-7	3-(2-Aminoethylamino)propyl]trimethoxysilane	28.1	0 (f)	0.33 (f)	60 (f)	I	27.6	0 (f)	0.41 (f)	73 (f)	I	27.6	0 (f)	0.35 (f)	63 (f)	I
3-8	Sodium dodecyl sulfate	28.4	0 (f)	0.45 (f)	81 (f)	I	27.6	0 (f)	0.46 (f)	82 (f)	I	27.6	0 (f)	0.38 (f)	70 (f)	I
3-9	m-Phenylenediamine	27.0	0 (f)	0.39 (f)	70 (f)	I	27.6	0 (f)	0.42 (f)	74 (f)	I	26.9	0 (f)	0.38 (f)	69 (f)	I
3-10	Tetraethylene glycol	27.8	0 (f)	0.24 (f)	43 (f)	I	27.7	0 (f)	0.20 (f)	35 (f)	I	26.9	20 (f)	0.21 (f)	38 (f)	I
3-30	Imidazole	28.1	90 (f)	0.24 (f)	23 (f)	I	27.8	80 (f)	0.31 (f)	33 (f)	I	27.7	90 (f)	0.24 (f)	24 (f)	I
3-32	Sodium salicylate	27.7	0 (f)	0.54 (f)	43 (f)	I	27.5	0 (f)	0.35 (f)	38 (f)	I	28.0	0 (f)	0.47 (f)	43 (f)	I
3-11	gamma-Butyrolactone	27.5	0 (f)	0.22 (f)	40 (f)	I	27.7	10 (f)	0.23 (f)	42 (f)	I	26.9	0 (f)	0.21 (f)	37 (f)	I
3-12	Methyl acetate	28.4	0 (f)	0.20 (f)	36 (f)	I	27.6	0 (f)	0.18 (f)	32 (f)	I	26.9	0 (f)	0.18 (f)	32 (f)	I
3-13	Myristyl alcohol	27.1	190 (NI)	-0.02 (NI)	0 (NI)	NI	27.3	190 (NI)	-0.05 (NI)	0 (NI)	NI	28.2	190 (NI)	-0.03 (NI)	0 (NI)	NI
3-14	2,6-Dichlorobenzoyl chloride	28.0	190 (NI)	0.00 (NI)	21 (NI)	NI	27.3	110 (f)	0.46 (f)	33 (f)	I	28.2	190 (NI)	-0.07 (NI)	0 (NI)	NI
3-15	Dibenzyl phosphate	28.1	0 (f)	0.51 (f)	71 (f)	I	27.3	0 (f)	0.39 (f)	59 (f)	I	28.2	0 (f)	0.32 (f)	57 (f)	I
3-17	1-(2-Propoxy-1-methylethoxy)-2-propanol	27.8	0 (f)	0.36 (f)	37 (f)	I	27.4	0 (f)	0.21 (f)	39 (f)	I	28.1	0 (f)	0.21 (f)	38 (f)	I
3-18	Camphene	27.7	160 (f)	0.08 (f)	4 (NI)	I	27.3	190 (NI)	-0.03 (NI)	0 (NI)	NI	28.4	190 (NI)	-0.01 (NI)	0 (NI)	NI
3-19	Ethyl-2-methylacetoacetate	27.2	0 (f)	0.25 (f)	46 (f)	I	27.5	10 (f)	0.19 (f)	34 (f)	I	28.3	0 (f)	0.23 (f)	42 (f)	I
3-20	Propylene glycol propyl ether	28.1	0 (f)	0.23 (f)	42 (f)	I	27.5	10 (f)	0.20 (f)	36 (f)	I	28.3	0 (f)	0.23 (f)	42 (f)	I
3-31	2-Methyl-1-pentanol	27.9	0 (f)	0.42 (f)	75 (f)	I	27.5	0 (f)	0.26 (f)	48 (f)	I	28.0	0 (f)	0.27 (f)	49 (f)	I
3-33	α-Hexylcinnamaldehyde	27.4	190 (NI)	-0.04 (NI)	0 (NI)	NI	28.0	190 (NI)	-0.03 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.01 (NI)	0 (NI)	NI
3-37	Cyclopentanol	27.4	0 (f)	0.28 (f)	51 (f)	I	28.0	0 (f)	0.28 (f)	51 (f)	I	28.0	0 (f)	0.30 (f)	55 (f)	I
3-21	Methyl amyl ketone	27.4	10 (f)	0.10 (f)	20 (f)	I	27.2	30 (f)	0.16 (f)	26 (f)	I	28.3	20 (f)	0.12 (f)	21 (f)	I

3-22	2- (n-Dodecylthio)ethanol	28.7	190 (NI)	-0.05 (NI)	0 (NI)	NI	27.4	190 (NI)	0.00 (NI)	0 (NI)	NI	28.3	190 (NI)	-0.02 (NI)	0 (NI)	NI
3-23	iso-Octylthioglycolate	27.3	190 (NI)	0.00 (NI)	2 (NI)	NI	27.4	190 (NI)	-0.02 (NI)	0 (NI)	NI	27.4	190 (NI)	-0.02 (NI)	0 (NI)	NI
3-24	2,4-Difluoronitrobenzene	27.8	30 (I)	0.13 (I)	20 (I)	I	27.4	40 (I)	0.11 (I)	18 (I)	I	27.4	50 (I)	0.10 (I)	16 (I)	I
3-25	tetra-Aminopyrimidine sulfate	28.7	190 (NI)	-0.09 (NI)	0 (NI)	NI	27.2	190 (NI)	-0.09 (NI)	0 (NI)	NI	27.4	190 (NI)	-0.07 (NI)	0 (NI)	NI
3-26	2,4-Pentanediol	27.4	120 (I)	0.08 (I)	7 (I)	I	27.6	130 (I)	0.12 (I)	8 (I)	I	27.4	10 (I)	0.11 (I)	19 (I)	I
3-27	iso-Octyl acrylate	27.9	190 (NI)	0.00 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.01 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.02 (NI)	0 (NI)	NI
3-28	Silicon dioxide n-hydrate	27.3	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.8	190 (NI)	-0.04 (NI)	0 (NI)	NI	27.7	190 (NI)	-0.04 (NI)	0 (NI)	NI
3-29	Potassium tetrafluoroborate	27.8	0 (I)	0.45 (I)	13 (I)	I	27.7	0 (I)	0.47 (I)	14 (I)	I	27.7	0 (I)	0.53 (I)	16 (I)	I
3-34	n,n-Dimethylguanidine sulfate	27.8	0 (I)	0.40 (I)	32 (I)	I	27.7	0 (I)	0.84 (I)	25 (I)	I	28.0	0 (I)	1.44 (I)	29 (I)	I
3-35	Toluene	28.0	80 (I)	0.16 (I)	19 (I)	I	27.7	30 (I)	0.12 (I)	20 (I)	I	28.0	110 (I)	0.07 (I)	7 (I)	I
3-36	Gluconolactone	27.2	0 (I)	0.26 (I)	10 (I)	I	27.5	0 (I)	0.31 (I)	9 (I)	I	28.0	0 (I)	0.33 (I)	7 (I)	I

*Temperature of the model at the time of exposure to the test chemical solution

190 Table 20. Results for Phase III control chemicals

Chemical	FDSC			BRC			Daicel		
	1	2	3	1	2	3	1	2	3
Negative control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-
Positive control	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-
Reference	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass	-

191

192 Table 21. Results for Phase III test chemicals

GHS	No.	Test chemical	FDSC	BRC	Daicel	Lead Lab
Category 1	3-2	2-Benzyl-4-chlorophenol	I	I	I	I
	3-4	Captan	NI	NI	NI	NI
	3-6	Butanol	I	I	I	I
	3-7	3-(2-Aminoethylamino)propyl] trimethoxysilane	I	I	I	I
	3-9	m-Phenylenediamine	I	I	I	I
	3-10	Tetraethylene glycol	I	I	I	I
	3-30	Imidazole	I	I	I	I
	3-32	Sodium salicylate	I	I	I	I
Cat. 2A & 2B	3-11	gamma-Butyrolactone	I	I	I	I
	3-12	Methyl acetate	I	I	I	I
	3-14	2,6-Dichlorobenzoyl chloride	NI	I	NI	I
	3-15	Dibenzyl phosphate	I	I	I	I
	3-17	1-(2-Propoxy-1-methylethoxy)-2-propanol	I	I	I	I
	3-18	Camphene	I	NI	NI	I
	3-19	Ethyl-2-methylacetoacetate	I	I	I	I
	3-20	Propylene glycol propyl ether	I	I	I	I
	3-31	2-Methyl-1-pentanol	I	I	I	I
	3-37	Cyclopentanol	I	I	I	I
No Category	3-21	Methyl amyl ketone	I	I	I	I
	3-22	2-(n-Dodecylthio)ethanol	NI	NI	NI	NI
	3-23	iso-Octylthioglycolate	NI	NI	NI	NI
	3-24	2,4-Difluoronitrobenzene	I	I	I	I
	3-26	2,4-Pentanediol	I	I	I	I
	3-27	iso-Octyl acrylate	NI	NI	NI	NI
	3-29	Potassium tetrafluorobroate	I	I	I	I

	3-34	n,n-Dimethylguanidine sulfate	I	I	I	I
	3-36	Gluconolactone	I	I	I	NI
	3-1	2,5-Dimethyl-2,5-hexanediol	I	I	I	I
	3-3	2,2-Dimethyl butanoic acid	I	I	I	I
	3-5	Tetra-n-octylammonium bromide	I	I	NI	I
	3-8	Sodium dodecyl sulfate	I	I	I	I
Unknown	3-13	Myristyl alcohol	NI	NI	NI	NI
	3-33	α -Hexylcinnamaldehyde	NI	NI	NI	I
	3-25	tetra-Aminopyrimidine sulfate	NI	NI	NI	NI
	3-28	Silicon dioxide n-hydrate	NI	NI	NI	NI
	3-35	Toluene	I	I	I	I

193 *In-house data from the lead lab was obtained from non-coded chemicals.

194

195 Table 22-1. Phase III contingency table used at FDSC and BRC in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	16	2	18
	No Category	6	3	9
Total		22	5	27

Sensitivity: 88.9% (16/18)

Specificity: 33.3% (3/9)

Accuracy: 70.4% (19/27)

196

197 Table 22-2. Phase III contingency table used at Daicel in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	15	3	18
	No Category	6	3	9
Total		21	6	27

Sensitivity: 83.3% (15/18)

Specificity: 33.3% (3/9)

Accuracy: 66.7% (18/27)

198

199 Table 22-3. Phase III contingency tables used at the lead lab in bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	17	1	18
	No Category	5	4	9
Total		22	5	27

Sensitivity: 94.4% (17/18)

Specificity: 44.4% (4/9)

Accuracy: 77.8% (21/27)

200

201

Table 23. Limitations on applicability at a bottom-up approach in phase III

No.	Test chemicals	Rank	Applicability limitation
3-4	Captan	False negatives	Insoluble after 5 m.
3-14	2,6-Dichlorobenzoyl chloride		pH of 2.5% solution < 5.0
3-18	Camphene		Protocol revised
3-21	Methyl amyl ketone	False positive	
3-24	2,4-Difluoronitrobenzene		
3-26	2,4-Pentanediol		
3-29	Potassium tetrafluoroborate		
3-34	n,n-Dimethylguanidine sulfate		
3-36	Gluconolactone		pH of 2.5% solution < 5.0 after 10 m.

202

203

4.2 Quality assurance

204

205

206

207

208

209

210

All the records (data sheets and record sheets) from the participating laboratories were checked by JaCVAM, As a result, six record sheets were uncompleted. They were the record sheets on the maintenance of measuring instruments, the culture of HCE models, and the preparation and application of test chemicals at phase I and the preparation and application of test chemicals at phase II in BRC, and application of test chemicals at phase I and phase III in Daicel. Although there are these defectiveness records, JaCVAM considered these records had less effects on quality of data in the validation study.

211

5 Discussion

212

5.1 Purpose of the Validation

213

214

215

216

217

218

219

220

221

222

223

The validation study was conducted to assess the reliability (within- and between-laboratory reproducibility) and relevance (predictive capacity) of the Vitrigel-EIT method with a challenging set of test chemicals for which high quality in vitro and in vivo data are available. Preference should be given the selection of test chemicals that were classified under UN GHS using individual animal. Unfortunately, the VMT is unable to establish a correlation between results obtained using the Vitrigel-EIT method and EPA categories due to a lack of individual animal data. Therefore, results obtained using the Vitrigel-EIT method are correlated with UN GHS categories only. The Vitrigel-EIT method was developed primarily to identify ocular non-irritants in a bottom-up approach. The VMT also undertook an analysis of a top-down approach to identifying UN GHS Category 1 ocular irritants for comparison with the results from a bottom-up approach.

224

5.2 Transferability

225

226


All test chemicals were successfully identified during Phase 0 in conformance with the results from the lead laboratory, and the protocol was then revised from ver. 1.30e to ver. 1.51e. Further revisions

227 were made to eliminate inconsistencies that were identified during Phase I and Phase II testing. The
 228 VMT confirmed that these inconsistencies had been resolved, thereby validating transferability of the
 229 test method. A history of revisions made to the Vitrigel-EIT protocol during this process is shown in
 230 Fig.7. Significant milestones during this process include:

- 231 · Changed the positive control from ethanol to benzalkonium chloride
- 232 · Adopted ethanol as reference control for checking the quality of the HCE models
- 233 · Defined a procedure for dissolving test chemicals in the culture medium (Fig.3)
- 234 · Defined a standard ambient temperature for the experiment
- 235 · Revised other minor points in the protocol

236 In order to check of transferability for regulatory use, a representative set of proficiency chemicals
 237 address for regulatory acceptance in appendix 8.9.

238



239

240 Fig. 7 Vitrigel-EIT protocol revision history

241 5.3 Within- and between-laboratory reproducibility

242 The results of Phase I showed that within-laboratory reproducibility was 80% at FDSC, 90% at Daicel,
 243 and 100% at BRC, which was sufficient to satisfy the success criteria of 80% as stated in the study
 244 plan. The results of Phase II, however, were problematic and not accepted by the VMT, because
 245 irrespective of the fact that the results satisfied success criteria for between-laboratory reproducibility,
 246 all three participating laboratories obtained a false-negative result for imidazole, a GHS Category 1
 247 irritant. The results of Phase III showed that imidazole was identified correctly by all laboratories and
 248 that overall between-laboratory reproducibility was 90%, which was sufficient to satisfy the success
 249 criteria of 80% as stated in the study plan. Thus, the VMT concluded that through the process of
 250 revising the test protocol, the Vitrigel-EIT method attained an elevated level of between-laboratory
 251 reproducibility.

252 On the other hand, there were nine test chemicals that were used in both Phases II and III. Although
 253 there was a significant difference between Phases II and III in the temperature at which measurements

254 were made, results of 7 of these 9 test substances were concordant. Only imidazol and toluene were
255 not concordant between Phases II and III. In order to predict imidazole correctly as an irritant, the
256 temperature at which measurements were made was revised in the protocol prior to Phase III.
257 Regarding the inconsistencies for toluene in Phase II, Daicel and BRC performed the test at 22 to
258 25°C and predicted it to be a non-irritant, although FDSC performed the test at a relatively high 24 to
259 26°C and predicted it to be an irritant (Table 18). However, in Phase III, all three laboratories tested
260 at 28±2°C and predicted toluene to be an irritant. These results suggest that the temperature at which
261 measurements are made is important for achieving reproducible results. Therefore, this data also
262 indicates a high between-laboratory reproducibility for this test method.
263

264 **5.4 Predictive capacity and relevance**

265 The results obtained from thirty-six test chemicals during Phase III were analyzed to assess their
266 correlation with both existing in vitro and in vivo data and thereby evaluate predictive capacity. The
267 Vitrigel-EIT method was developed primarily to identify ocular non-irritants in a bottom-up approach.
268 Therefore, the test chemicals included UN GHS category 1, 2, 2A and 2B ocular irritants for which in
269 vivo data was available. The Vitrigel-EIT method demonstrated an accuracy of between 66.7 and
270 70.4 % (18 to 19/27), a sensitivity of between 88.3 and 88.9 % (15 to 16/18), and a specificity of
271 33.3% (3/9). Sensitivity was low due to three false negatives and specificity (predictive capacity for
272 identifying non-irritants) was low due to six false positives, as shown in Table 23. The VMT requested
273 the further analysis to determine whether or not predictive capacity could be improved by defining
274 the applicability domain. Ultimately, it was determined that although the results of the validation
275 confirmed an elevated level of reproducibility for this assay, the sample size was insufficient either to
276 evaluate predictive capacity or define a proper applicability domain. Therefore, the VMT
277 recommended that data obtained at the lead laboratory should be used to define an applicability
278 domain suitable for use in a regulatory context.

279 Total 114 test chemicals were tested at the lead laboratory (Appendix 8.8 and Appendix 8.11, law
280 data). Hence, the predictive capacity was evaluated by the 114 results comprise the data for 27 of
281 the 36 chemicals during Phase III shown in Table 21 and for 87 chemicals obtained at the lead laboratory
282 shown in Appendix 8.8. The test chemicals were selected to ensure that a diverse range of substances
283 were represented, and aspects such as eye-irritant level per UN GHS categories, physical state,
284 chemical class. Also, quality and reliability of in vivo data for the chemicals were carefully considered
285 by reference to the Draize eye test Reference Database (Adriaens et al., 2014; Barroso et al, 2017).
286 The 114 test chemicals are composed of 89 liquids and 25 solids. Also, their contents are 27
287 Category 1 chemicals, 1 Category 2 or higher, 1 Category 2, 5 Category 2A or higher, 15 Category
288 2A, 2 Category 2B or higher and 11 Category 2B chemicals, and 52 No Category chemicals by UN
289 GHS classification. There were 27 coded chemicals tested for Phase III and 87 non-coded chemicals
290 were tested at the lead laboratory. These 114 test chemicals were examined by the Vitrigel-EIT method
291 in accordance with the protocol versions described in Chapter 3.1.3.4 and Appendix 8.8. However,
292 the temperature at which all measurements were made during the chemical exposure experiments was
293 strictly controlled at 28±2°C (Table 19 and Appendix 8.8). Thus we consider this data sufficient for
294 assessing the suitability of the Vitrigel-EIT method for use in a bottom-up approach for identifying

295 ocular non-irritants and in a top-down approach for identifying UN GHS Category 1 ocular irritants.
 296 In a bottom-up approach, 75 of the test chemicals were classified as irritant and the other 39 as non-
 297 irritant, with results for 85 of the 114 test chemicals matching their UN GHS categories. In contrast,
 298 8 of the 62 test chemicals classified as irritants by in vivo data were identified as non-irritants, a false-
 299 negative rate of 13%. Additionally, 21 of the 52 test chemicals classified as non-irritants under UN
 300 GHS were identified as irritants, a false-positive rate of 40%. Thus, the Vitrigel-EIT method achieved
 301 a sensitivity of 87%, a specificity of 60%, and an accuracy of 75%, as shown in Table 24-1. Data from
 302 the lead laboratory also demonstrated that predictive capacity could be improved by expanding the
 303 sample size. For example, the specificity achieved in Phase III of this validation study was lower than
 304 that obtained from the data of 52 non-irritants resulted in a higher specificity. The list of test chemicals
 305 that were either false negative or false positives is shown in Table 25.
 306 On the other hand, analysis per a top-down approach for identifying UN GHS Category 1 ocular
 307 irritants was also performed as a part of this validation study, as shown in Tables 24-2. Regarding
 308 identifying test chemicals classified as UN GHS Category 1 in a top-down approach, the Vitrigel-EIT
 309 method demonstrated a sensitivity of 89% (24/27), a specificity of 41% (36/87), and an accuracy of
 310 53% (60/114). Specificity is an important criterion in a top-down approach, which means that Vitrigel-
 311 EIT method is not well suited for use in a top-down approach to identifying UN GHS Category 1
 312 ocular irritants.

313 Table 24-1. Contingency table used for 114 test chemicals in a bottom-up approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	54	8	62
	No Category	21	31	52
Total		75	39	114

Sensitivity: 87.1% (54/62)

Specificity: 59.6% (31/52)

Accuracy: 74.6% (85/114)

314 Table 24-2. Contingency table used for 114 test chemicals in a top-down approach

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1	24	3	27
	Cat.2A, 2B, No Category	51	36	87
Total		75	39	114

Sensitivity: 88.9% (24/27)

Specificity: 41.4% (36/87)

Accuracy: 52.6% (60/114)

315

316
317
318
319
320
321
322

Table 25. False test chemicals in a bottom-up approach for 114 test chemicals

No.*	Test chemicals	Rank	Applicability limitation
11	Lactic acid	False negative	pH of 2.5% solution \leq 5.0
14	Captan		Insoluble after 5 m
22	Acetic acid (10%)		pH of 2.5% solution \leq 5.0
41	3,3'-Dithiodipropionic acid		pH of 2.5% solution \leq 5.0
46	2,6-Dichlorobenzoyl chloride		pH of 2.5% solution \leq 5.0
54	Camphene		Protocol revised
55	Ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridinepropanoate		pH of 2.5% solution \leq 5.0
62	Glycolic acid (10%)		pH of 2.5% solution \leq 5.0
66	Gluconolacton	False positive	pH of 2.5% solution $<$ 5.0 after 10 m
67	Methyl amyl ketone		
68	Methyl isobutyl ketone		
69	<i>N,N</i> -Dimethylguanidine sulfate		
70	Glycerol		
75	2-Ethoxyethyl acetate		
76	Ethyl acetate		
77	2,4-Pentanediol		
78	Triethanolamine		
85	Cyclohexanone		
89	2,4-Pentanedione		
90	Butyl acetate		
91	Xylene		
93	EDTA, di-potassium		
94	3-Glycidoxypropyltrimethoxysilane		
96	Ethyl trimethyl acetate		
97	2,2-Dimethyl-3-pentanol		
98	Betaine monohydrate		
104	1,2,3-trichloropropane		
108	2,4-Difuroronitrobenzene		
109	Potassium tetrafluoroborate		

323 *Each number corresponds to the number in Table 21 and Appendix 8.8.

324 **5.7 Applicability domain**

325 Analysis of the false-negative reactions shows that six of the eight false-negative chemicals were
326 acidic, and the 2.5% solutions used for exposure had a pH level lower than 5, as shown in Table 25.
327 The TEER values of the HCE models after exposures to each of these six acidic test chemicals that
328 yielded false-negatives increased from their initial values. Interestingly, it was reported that isolated
329 rabbit esophageal mucosal epithelium and normal human bronchial epithelial cell layers in culture
330 displayed increased TEER values when exposed to weak acidic solutions (Farré et al., 2008; Oshima
331 et al., 2012). On the other hand, one of the two non-acidic false-negative chemicals were water-
332 insoluble solids that were easily separated from the culture medium at room temperature, as shown in
333 Table 25. Therefore, the lead laboratory added two restrictions to the applicability domain in
334 consideration of above scientific rationales:

- 335 • Exclude all test chemicals that have a pH level of 5 or less in solution (affected 9 tested
336 chemicals).
- 337 • Exclude all solids that have both a logP value of 2.5 or more and a density of either less than
338 0.95 g/cm³ or over 1.10 g/cm³ (affected 3 test chemicals).

339 Under this applicability domain, 12 of the original 114 test chemicals were excluded, as shown in
340 Tables 26, which improve sensitivity from 87 to 98%, specificity from 60 to 61%, and accuracy from
341 75 to 79%, as shown in Table 27.

342

343 Eight of the 36 test chemicals in Phase III are excluded under the new applicability domain:

- 344 No. 3-2 2-Benzyl-4-chlorophenol (insoluble)
- 345 No. 3-3 2,2-Dimethyl butanoic acid (pH ≤ 5)
- 346 No. 3-4 Captan (insoluble)
- 347 No. 3-5 tetra-n-Octylammonium bromide (insoluble)
- 348 No. 3-13 Myristyl alcohol (insoluble)
- 349 No. 3-14 2,6-Dichlorobenzoyl chloride (pH ≤ 5)
- 350 No. 3-15 Dibenzyl phosphate (pH ≤ 5)
- 351 No. 3-25 tetra-aminopyrimidine sulfite (pH ≤ 5)

352 After excluding these eight test chemicals, sensitivity improved from between 75 and 83% to between
353 88 and 94% (15 to 16/17), specificity changed from 42% to 36% (4/11), and accuracy improved from
354 between 64 and 69% to between 68 and 71% (19 to 20/28).

355 Of the 17 irritants, two others that yielded false-negatives were No. 3-18, camphene, and No. 3-33,
356 alpha-hexylcinnamaldehyde. Camphene is a waxy, water-insoluble solid, and the false-negative was
357 due to the technique used for dissolving, as described in section 4.1.4 Phase III. Alpha-
358 hexylcinnamaldehyde is a water-immiscible liquid and was identified as an irritant by the lead
359 laboratory (Yamaguchi, 2016). The reason for the discordance of the judgment is currently under
360 investigation although the classification of alpha-hexylcinnamaldehyde in several studies in vivo was
361 reported as NC and 2A or higher (Barroso et al, 2017).

362

363 Table 26-1. Limitations on applicability (pH level 5 or less in 2.5% solution) in a bottom-up approach

No.*	Test chemical	GHS category	Vitrigel-EIT results	pH
11	Lactic acid	1	False negative	3
22	Acetic acid (10%)	1	False negative	4
41	3,3'-Dithiodipropionic acid	2A	False negative	4
46	2,6-Dichlorobenzoyl chloride	2A	False negative	3
47	Dibenzyl phosphate	2A		3
55	Ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridinepropanoate	2B	False negative	5
56	3-Chloropropionitrile	2B		5
62	Glycolic acid (10%)	2B	False negative	4
93	EDTA,di-potassium	NC	False positive	5

364 *Each number corresponds to the number in Table 21 and Appendix 8.8.

365

366

367

368

369

370

371

372

373 Table 26-2. Limitations on applicability (solid chemicals with a logP value of 2.5 or more and a density
374 under 0.95 g/cm³ or over 1.10 g/cm³ in a bottom-up approach.

No.*	Test chemical	GHS category	Vitrigel-EIT results	LogP	Density (g/cm ³)
10	Acid red 92	2		7.13	2.16
13	2-Benzyl-4-chlorophenol	1		3.60	1.19
14	Captan	1	False negative	2.80	1.74

375 *Each number corresponds to the number in Table 21 and Appendix 8.8

376 Table 27. Contingency tables used for 102 test chemicals within the applicability domain in bottom-
377 up approach.

		Vitrigel-EIT		Total
		I	NI	
UN GHS	Cat.1, 2A, 2B	50	1	51
	Not Classified	20	31	51
Total		70	32	102

Sensitivity: 98.0% (50/51)

Specificity: 60.8% (31/51)

Accuracy: 79.4% (81/102)

378

379 **5.6 Other analysis**

380 The VMT discussed the use of an area over the curve (or weighted area under the curve: wAUC) of
381 the TEER measurement to obtain high predictive capacity and requested that the biostatisticians
382 develop new prediction algorithm. As a result, a new statistical algorithm was designed and proposed
383 to improve the predictive capacity, particularly in the area of specificity.

384 The proposed algorithm involved evaluating the eye irritancy of a test chemical using two parameters:
385 (1) the TEER value measured at the final time point (180 seconds) and (2) the decrease in TEER value
386 across the 180-second measurement period. A suitable cut-off value was determined for these two
387 parameters based on the results of Phase III and in reference to the Youden index. The sensitivity,
388 specificity, and accuracy obtained with the proposed algorithm were then compared with those
389 obtained with the original algorithm. Finally, the validity of the proposed algorithm was confirmed
390 using the results obtained from 118 test chemicals by the lead laboratory (Yamaguchi et al., 2016).

391 Using a cut-off value of 0.15 for the decrease in TEER value across the measurement period yielded
392 a sensitivity of 67%, a specificity of 92%, and an accuracy of 75%. Based on these results, the VMT
393 decided not to accept the new prediction algorithm to analyze data from this validation study.

394

395 **5.7 Comparison with other alternative to ocular irritation assay**

396 The Vitrigel-EIT method was developed by measuring relative changes in TEER for a period of 180
397 second after exposure to 30 test chemicals as previously reported (Yamaguchi et al., 2013). It is
398 generally accepted that at least 100 substances should be tested to assess the predictive capacity of a
399 new test method, and to this end, the developers tested a total of 118 test chemicals of various physical
400 and chemical properties (Yamaguchi et al., 2016). The results of this testing showed that the Vitrigel-
401 EIT test method had a predictive capacity that was comparable to other test methods for which OECD
402 test guidelines are currently being developed. For example, the EpiOcular-EIT method demonstrated
403 a sensitivity of 98%, a specificity of 73%, and an accuracy of 85% (Kaluzhny et al., 2011). Used in a
404 bottom-up approach, the short time exposure (STE) test demonstrated a sensitivity of 88%, a
405 specificity of 80%, and an accuracy of 85% (ICCVAM, 2013) and the predictive capacity of the
406 Vitrigel-EIT method is similar with ones of the other methods (the sensitivity of 93%, a specificity of
407 69%, and an accuracy of 83%) under the applicability domain.

408 In addition, the vitrigel-EIT method has some advantages in required time, practicality and cost shown
409 in Table 28. Each of these test methods, however, yields some false-negatives or false-positives. Thus,
410 it is important to clarify the mechanism that results in these false-negatives and false-positives,
411 particularly when developing an in vitro test method suitable for use as an alternative to in vivo testing.
412 The VMT has confirmed the applicability domain proposed by the lead laboratory. Meanwhile,
413 scientists at the lead laboratory consider immuno-histology to be a powerful tool for clarifying the
414 mechanism of false-positive reactions, because the culture model can be easily utilized as frozen
415 sections after completing the Vitrigel-EIT.

416

417 Table 28. Comparative table between the Vitrigel-EIT method and other test methods.

Test method	Vitrigel-EIT	STE (TG491)	EpiOcular-EIT (TG492)
Required time (for 24 test)	6days for preparing HCE models 2hours for chemicals exposure experiment	4days for preparing SIRC cell monolayer 3hours for chemical exposure experiment	1day for preparing HCE models 9hours (liquid) or 30hours (solid) for chemical exposure experiment
Practicality	Easy	Easy	Difficult to remove test chemicals from HCE models
Cost	¥84,000 for ad-MED Vitrigel	Relatively low	¥144,000 for HCE models
Mechanistic relevance	Epithelial barrier function	Cell viability	Cell viability
Limitation of test chemicals	Exclude acidic and easily separable water-insoluble solids	Exclude highly volatile substances and all solid chemicals other than Surfactants	Colored sample (need additional procedure)

418
419
420

6 Conclusion

This study was performed in the spirit of GLP at three participating laboratories using a total of 42 test chemicals to validate the Vitrigel-EIT method for within- and between-laboratory reproducibility as well as for the capacity to distinguish non-irritants from irritants in a bottom up approach.

The results showed good within-laboratory reproducibility between 80 and 100% as well as an excellent between-laboratory reproducibility of 92% (33/36). Unfortunately, predictive capacity for distinguishing non-irritants from irritants per UN GHS categories in a bottom-up approach was not favorable because of a high incidence of false negatives as high as 13% (8/62) with in house data. After considerable review of the data, the applicability domain was revised to exclude test chemicals that have a pH level of 5 or less in solution as well as those that are solids and have both a logP value 2.5 or more and a density of either less than 0.95 g/cm³ or a density of over 1.10 g/cm³, which improved the false negative rate to 2% (1/51).

From the above described results, the VMT concluded that the Vitrigel-EIT method demonstrated excellent within- and between-laboratory replicability and that, with a carefully defined applicability domain, it is a useful alternative to the Draize test for distinguishing test chemicals that are ocular non-irritants from those that are irritants.

Acknowledgments

This work was supported by Agri-Health Translational Research Project (no. 6320) from the Ministry of Agriculture, Forestry and Fisheries of Japan.

7 References

- Adriaens, E., Barroso, J., Eskes, C., Hoffmann, S., McNamee, P., Alépée, N., Bessou-Touya, S., De Smedt, A., De Wever, B., Pfannenbecker, U., Tailhardat, M., and Zuang, V., “Retrospective analysis of the Draize test for serious eye damage/eye irritation: importance of understanding the in vivo endpoints under UN GHS/EU CLP for the development and evaluation of in vitro test methods,” *Archives of toxicology* 88 (2014): 701–723.
- Araki-Sasaki, K., Ohashi, Y., Sasabe, T., Hayashi, K., Watanabe, H., Tano, Y., and Handa, H., “An SV40-immortalized human corneal epithelial cell line and its characterization,” *Investigative Ophthalmology & Visual Science* 36 (1995): 614–621.
- Barroso, J., Pfannenbecker, U., Adriaens, E., Alépée, N., Cluzel, M., De Smedt, A., Hibatallah, J., Klaric, M., Mewes, K.R., Millet, M., Templier, M., and McNamee, P., “Cosmetics Europe compilation of historical serious eye damage/eye irritation in vivo data analysed by drivers of classification to support the selection of chemicals for development and evaluation of alternative methods/strategies: the Draize eye test Reference Database (DRD),” *Archives of toxicology* 91 (2017): 521–547.
- Kim, C. W., Go, R. E., Lee, G. A., Kim, C. D., Chun, Y. J., and Choi, K. C., “Immortalization of human corneal epithelial cells using simian virus 40 large T antigen and cell characterization,” *Journal of Pharmacological and Toxicological Methods* 78 (2016): 52–57.
- Draize, J., Woodard, G., and Calvery, H., “Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes,” *The Journal of Pharmacology and*

462 *Experimental Therapeutics* 82 (1944): 377–390.

463 European Centre for Ecotoxicology and Toxicology of Chemicals, *TR 048 Eye Irritation: Reference*
464 *Chemicals Data Bank*, 2nd ed., Brussels: ECETC, 1998.

465 Farré, R., van Malenstein, H., De Vos, R., Geboes, K., Depoortere, I., Vanden Berghe, P., Fornari, F.,
466 Blondeau, K., Mertens, V., Tack, J., and Sifrim, D., “Short exposure of esophageal mucosa to
467 bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and
468 provoke dilated intercellular spaces,” *Gut*. 57 (2008): 1366–1374.

469 Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M.,
470 Hoffmann, S., Janusch Roi, A., Prieto, P., Sabbioni, E., Scott, L., Worth, A., and Zuang, V., “A
471 modular approach to the ECVAM principles on test validity,” *ATLA* 32 (2004): 467–472.

472 National Institute of Environmental Health Sciences, “Appendix J: NICEATM Analysis: Reduced
473 Eye Hazard Labeling Resulting from Using Globally Harmonized System (GHS) Instead of
474 Current U.S. Regulatory Classification Criteria,” *ICCVAM Test Method Evaluation Report:
475 Current Validation Status of In Vitro Test Methods Proposed for Identifying Eye Injury Hazard
476 Potential of Chemicals and Products*, National Institutes of Health Publication No. 10-7553,
477 National Institutes of Health (2010):
478 http://ntp.niehs.nih.gov/iccvam/docs/ocutox_docs/invitro-2010/appj-analysis.pdf.

479 *Short Time Exposure (STE) Test Method Summary Review Document*, National Institutes of Health
480 (2013): http://ntp.niehs.nih.gov/iccvam/docs/ocutox_docs/STE-SRD-NICEATM-508.pdf.

481 Kaluzhny, Y., Kandárová, H., Hayden, P., Kubilus, J., d’Argembeau-Thornton, L., and Klausner, M.,
482 “Development of the EpiOcular™ Eye Irritation Test for Hazard Identification and Labelling
483 of Eye Irritating Chemicals in Response to the Requirements of the EU Cosmetics Directive
484 and REACH Legislation,” *ATLA* 39 (2011): 339–364.

485 Cooper-Hannan, R., Harbell, J., and Coecke, S., “The principles of good laboratory practice:
486 application to in vitro toxicology studies,” *ATLA* 27 (1999): 539–577

487 Organisation for Economic Co-operation and Development, *Principles of Good Laboratory Practice
488 and Compliance Monitoring*, OECD ENV/MC/CHEM (98)17 (1998):
489 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/mc/chem\(98\)17&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/mc/chem(98)17&doclanguage=en).

490

491 *OECD Series on Testing and Assessment, Number 34: Guidance Document on the Validation and
492 International Acceptance of New or Updated Test Methods for Hazard Assessment*, OECD
493 ENJ/JM/MONO(2005)14, OECD Publishing (2005):
494 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO\(2005\)14&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2005)14&doclanguage=en).

495

496 “Test No. 491: Short Time Exposure In Vitro Test Method for Identifying i) Chemicals Inducing
497 Serious Eye Damage and ii) Chemicals Not Requiring Classification for Eye Irritation or
498 Serious Eye Damage,” *OECD Guidelines for the Testing of Chemicals, Section 4*, OECD
499 Publishing (2015): <http://dx.doi.org/10.1787/9789264242432-en>.

500 “Test No. 492: Reconstructed human Cornea-like Epithelium (RhCE) Test Method for Identifying
501 Chemicals Not Requiring Classification and Labelling for Eye Irritation or Serious Eye
502 Damage,” *OECD Guidelines for the Testing of Chemicals, Section 4*, OECD Publishing (2015):

503 <http://dx.doi.org/10.1787/9789264242548-en>.

504 Scott, L., Eskes, C., Hoffmann, S., Adriaens, E., Alepée, N., Bufo, M., Clothier, R., Facchini, D., Faller,
505 C., Guest, R., Harbell, J., Hartung, T., Kamp, H., Varlet, B. L., Meloni, M., McNamee, P.,
506 Osborne, R., Pape, W., Pfannenbecker, U., Prinsen, M., Seaman, C., Spielmann, H., Stokes, W.,
507 Trouba, K., Berghe, C. V., Goethem, F. V., Vassallo, M., Vinardell, P., and Zuang, V., “A
508 proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom–Up
509 and Top–Down approaches,” *Toxicology In Vitro* 24 (2010): 1–9.

510 Takahashi, Y., Hayashi, K., Abo, T., Koike, M., Sakaguchi, H., and Nishiyama, N., “The Short Time
511 Exposure (STE) test for predicting eye irritation potential: Intra-laboratory reproducibility and
512 correspondence to globally harmonized system (GHS) and EU eye irritation classification for
513 109 chemicals,” *Toxicology In Vitro* 25 (2011): 1425–1434.

514 Takezawa, T., Ozaki, K., Nitani, A., Takabayashi, C., and Shimo-Oka, T., “Collagen vitrigel: a novel
515 scaffold that can facilitate a three-dimensional culture for reconstructing organoids,” *Cell*
516 *Transplantation* 13 (2004): 463–473.

517 Takezawa, T., Ozaki, K., and Takabayashi, C., “Reconstruction of hard connective tissue utilizing a
518 pressed silk sheet and type-I collagen as the scaffold for fibroblasts,” *Tissue Engineering*
519 (2007a) 13: 1357–1366.

520 Takezawa, T., Nitani, A., Shimo-Oka, T., and Takayama, Y., “A protein-permeable scaffold of a
521 collagen vitrigel membrane useful for reconstructing crosstalk models between two different
522 cell types,” *Cells, Tissues, Organs* 185 (2007b): 237–241.

523 Takezawa, T., Takeuchi, T., Nitani, A., Takayama, Y., Kino-Oka, M., Taya, M., and Enosawa S.
524 “Collagen vitrigel membrane useful for paracrine assays in vitro and drug delivery systems in
525 vivo,” *Journal of Biotechnology* 131 (2007c): 76–83.

526 Takezawa, T., McIntosh-Ambrose, W., and Elisseeff, J. H., “A novel culture model of rabbit corneal
527 epithelium utilizing a handy scaffold of collagen vitrigel membrane and its cryopreservation,”
528 *Alternatives to Animal Testing and Experimentation* 13 (2008): 176.

529 Takezawa, T., Nishikawa, K., and Wang, P. C., “Development of a human corneal epithelium model
530 utilizing a collagen vitrigel membrane and the changes of its barrier function induced by
531 exposing eye irritant chemicals,” *Toxicology In Vitro* 25 (2011a): 1237–1241.

532 Takezawa, T., Aoki, S., Oshikata, A., Okamoto, C., Yamaguchi, H., Narisawa, Y., and Toda, S., “A
533 novel material of high density collagen fibrils: A collagen xerogel membrane and its application
534 to transplantation in vivo and a culture chamber in vitro,” *24th European Conference on*
535 *Biomaterials* (2011b): 831 (Abstract).

536 “A novel material of high density collagen fibrils: A collagen xerogel membrane and its
537 application to transplantation in vivo and a culture chamber in vitro,” *24th European*
538 *Conference on Biomaterials*, Bologna: MEDIMOND, 2011c, 181–185.

539 Uematsu, M., Kumagami, T., Kusano, M., Yamada, K., Mishima, K., Fujimura, K., Sasaki, H., and
540 Kitaoka, T., “Acute corneal epithelial change after instillation of benzalkonium chloride
541 evaluated using a newly developed in vivo corneal transepithelial electric resistance
542 measurement method” *Ophthalmic Research* 39 (2007): 308–314.

543 United Nations, *Globally Harmonized System of Classification and Labeling of Chemicals*, 5th ed.

544 (ST/SG/AC.10/30/Rev.5), New York: United Nations, 2013.

545 Yamaguchi, H., Kojima, H., and Takezawa, T., “Vitrigel-eye irritancy test method using HCE-T cells,”
546 *Toxicological Sciences* 135 (2013): 347–355.

547 “Predictive performance of the Vitrigel-eye irritancy test method using 118 chemicals,” *Journal*
548 *of Applied Toxicology* 36 (2016): 1025–1037.

549 Yamasaki, K., Kawasaki, S., Young, R. D., Fukuoka, H., Tanioka, H., Nakatsukasa, M., Quantock,
550 A. J., and Kinoshita, S., “Genomic aberrations and cellular heterogeneity in SV40-
551 immortalized human corneal epithelial cells,” *Investigative Ophthalmology & Visual Science*
552 50 (2009): 604–613.

553 York, M., and Steiling, W., “A critical review of the assessment of eye irritation potential using the
554 Draize rabbit eye test,” *Journal of Applied Toxicology* 18 (1998): 233–240.

Vitrigel-Eye Irritation Test (EIT) method

Report of the Peer Review Panel

on

the validation study of the Vitrigel-EIT method to be used in a bottom-up approach for eye hazard identification according to the UN GHS classification

Final version, 19 October 2017

Table of Contents

1. Executive Summary	3
2. Peer Review Panel Composition	4
3. Background.....	5
4. Peer Review Panel Evaluation.....	6
4.1. Rationale for the test method	6
4.2. Toxicological mechanisms and relationship with the biological effect and toxicity of interest	6
4.3. Test method protocol	6
4.4. Within- and between-laboratory reproducibility	7
4.5. Selection of test chemicals	8
4.6. Predictive capacity.....	9
4.7. Data supporting the validity of the assay	10
4.8. Accordance with the principles of Good Laboratory Practices.....	11
4.9. Applicability Domain.....	11
4.10. Proficiency chemicals	11
4.11. Performance Standards	11
4.12. Advantages in terms of time, costs and animal welfare.....	12
4.13. Completeness of data and documents.....	12
4.14. Validation study management and conduct.....	12
4.15. Other considerations	12
5. Conclusions.....	13
6. Acknowledgements	13
7. References	14

1. Executive Summary

The present peer review panel (PRP) was established to independently evaluate the scientific validity of the Vitrigel-Eye Irritation Test (EIT) method to distinguish UN GHS No Category (No Cat.) test chemicals from test chemicals requiring classification according to the UN GHS classification scheme as e.g., an initial test in a bottom-up testing strategy approach (OECD GD 263, 2017). Vitrigel-EIT underwent a modular validation study (Anon., 2017a) coordinated by the Japanese Center for the Validation of Alternative Methods (JaCVAM) and conducted by an international Validation Management Team (VMT) comprised of representatives from the European Union Reference Laboratory for Alternatives to Animal Testing (EURL-ECVAM), the U.S. National Toxicology Program's Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM-ICCVAM) and the Korean Center for the Validation of Alternative Methods (KoCVAM).

The Vitrigel-EIT method, is based on a three dimensional human corneal epithelium (HCE) cultured on a Collagen Vitrigel Membrane (CVM) scaffold, and assesses the relative change over time of the Transepithelial Electrical Resistance (TEER) of epithelial cells as an endpoint for the integrity or disruption of the tight junction of the corneal epithelium (Anon., 2017a). The within- and betweenlaboratory reproducibility were of 90% (average of three laboratories) and 92% respectively, based on the testing of 10 and 36 coded chemicals (Anon., 2017a). The PRP considered these within- and between-laboratory reproducibility to be sufficient, but would have appreciated having further statistical justification for the number of chemicals used to assess the within-laboratory reproducibility.

Based on the results of the validation and of in-house studies, a reduced applicability domain was proposed by the VMT (Anon., 2017a), based on the following exclusion criteria: i) exclude test chemicals having a pH ≤ 5.0 based on 2.5% solution; ii) exclude solid test chemicals having both, log P ≥ 2.5 and density $< 0.95 \text{ g/cm}^3$ or $> 1.10 \text{ g/cm}^3$. The predictive capacity of the reduced applicability domain of Vitrigel-EIT was evaluated based on a total of 76 test chemicals representing 22 UN GHS Cat. 1, 22 UN GHS Cat. 2 and 32 UN GHS No Cat. chemicals, including both liquids and solids and covering a wide range of chemistries. A sensitivity of 93% (41/44), a specificity of 69% (22/32) and an accuracy of 83% (63/76) were found for the reduced applicability domain. Three false negatives (i.e. 7%) of 44 UN GHS classified test chemicals were found, all three being *in vivo* UN GHS Cat. 2 test chemicals (Anon., 2017a). The PRP considered this as an acceptable rate, as it is within the overall probability of about 12% of chemicals identified by the *in vivo* Draize eye test as either UN GHS Cat. 2 or UN GHS No Cat. in a repeated *in vivo* test, due to the *in vivo* method's inherent within-test variability (OECD GD 263, 2017).

Based on the above and the considerations described within this report, the PRP concluded that the Vitrigel-EIT method is valid for use as an initial test in a bottom-up testing strategy approach for identification of test chemicals not requiring classification and labelling for eye irritation or serious eye damage (UN GHS No Cat. chemicals), when used within the limited applicability domain of test chemicals having pH > 5.0 (based on 2.5% solution), and excluding solids having both a log P ≥ 2.5 and a density of $< 0.95 \text{ g/cm}^3$ or $> 1.10 \text{ g/cm}^3$.

2. Peer Review Panel Composition

Chantra Eskes (chair)	SeCAM, Switzerland
Pertti (Bert) Hakkinen	The National Library of Medicine, NIH, USA
Sebastian Hoffmann	seh consulting + services, Germany
Tae Cheon Jeong	Yeungnam University, Korea
Jill Merrill	FDA, USA
Sanae Takeuchi	P&G Innovation Godo Kaisha, Japan

3. Background

The Vitrigel-EIT method underwent a modular validation study coordinated by JaCVAM and conducted by an international Validation Management Team comprising representatives from EURLECVAM, NICEATM-ICCVAM and KoCVAM (Anon., 2017a). The validation study was designed to assess the usefulness of the Vitrigel-EIT test method as an alternative to the *in vivo* Draize test method to identify ocular non-irritants in a bottom-up testing strategy approach according to the UN GHS classification scheme.

The international Peer Review Panel (PRP) first met in July 2016 to discuss the outcome of the validation study with the Validation Management Team (VMT), and to review, in the absence of the VMT, the validation study of the Vitrigel-EIT method. The peer review of the Vitrigel-EIT validation study was conducted based on 14 evaluation criteria as requested by JaCVAM and summarized in Table 1. Upon requests for clarifications by the PRP on a number of elements, the VMT provided replies that were discussed via teleconferences in December 2016 and in June 2017. Based on suggestions from the PRP, the VMT carried out a final revision of the documentation addressing the open issues, which was distributed to the PRP in August 2017 (Anon., 2017a).

Table 1: Evaluation criteria guiding the peer review of the Vitrigel-EIT method.

Peer Review Evaluation criteria	
1	A rationale for the test method should be available, including a description of the human health effect, a clear statement of the scientific need, and the regulatory application
2	The toxicological mechanisms and the relationship between the test method endpoint(s) with the biological effect as well as the toxicity of interest should be addressed, describing limitations of the test method
3	A detailed test method protocol should be available
4	The within- and between-laboratory reproducibility of the test method should be demonstrated
5	Demonstration of the test method's performance should be based on testing of representative, preferably coded reference chemicals
6	Predictive capacity should be demonstrated using representative chemicals. The performance of the test method should be evaluated in relation to existing relevant toxicity data as well as information from the relevant target species
7	All data should adequately support the assessment of the validity of the test method for peer review
8	All data from the validation study supporting the validity of a test method should be obtained in accordance with the principles of Good Laboratory Practice (GLP)
9	Applicability domain of the test method should be defined
10	Proficiency chemicals should be set up in the proposed protocol
11	Performance standard should be set up with proposed protocol
12	Advantages in terms of time, cost and animal welfare

13	Completeness of all data and documents supporting the assessment of the validity of the test method
14	Validation study management and conduct

4. Peer Review Panel Evaluation

4.1. Rationale for the test method

The PRP agreed that a rationale for the test method has been provided, including a description of the human health effect and the regulatory application. Vitrigel-EIT is proposed as an alternative to the *in vivo* Draize eye irritation test method, to be used as an initial test in a bottom-up testing strategy approach (Anon., 2017a). Therefore, the validation study was designed to assess the capacity of Vitrigel-EIT to distinguish UN GHS No Cat. test chemicals from test chemicals requiring classification according to the UN GHS classification scheme.

4.2. Toxicological mechanisms and relationship with the biological effect and toxicity of interest

The PRP considered that the toxicological mechanisms and the relationship between the test method endpoint(s) with the biological effect as well as the toxicity of interest were briefly addressed within the validation report (Anon., 2017a), and were further addressed during a presentation given by the test method developers during the first PRP meeting in July 2016.

The Vitrigel-EIT method is based on a three dimensional air–liquid interface culture system composed of human corneal epithelium (HCE) cultured on a Collagen Vitrigel Membrane (CVM) scaffold comprising high-density collagen fibrils that are equivalent to *in vivo* connective tissues (Takezawa et al., 2011; Yamaguchi et al., 2013, 2016). The HCE model used is based on HCE-T cells, which is a SV40-immortalized cell strain (Araki-Sasaki et al., 1995), that can maintain stable characteristics of the corneal epithelial cells in culture (Kim et al., 2016, Yamasaki et al., 2009).

The Vitrigel-EIT method assesses the relative change over time of the Transepithelial Electrical Resistance (TEER) of epithelial cells as an endpoint for the integrity or disruption of the tight junction of the corneal epithelium. In particular, three parameters are used to correlate the TEER change over time to the prediction of eye hazard requiring classification: the TEER time lag, intensity and plateau level (Anon., 2017a, 2017b).

4.3. Test method protocol

The PRP concurred that a detailed test method protocol is available (Anon., 2017b) and the changes made during the validation study, as well as the rationale for these changes, are clearly described within the validation report and the protocol provided (Anon., 2017a, 2017b). Table 2 summarizes the main protocol changes undertaken during the different phases of the validation study.

Table 2. Overview of the different phases, evaluations and protocols used in the modular validation study of the Vitrigel-EIT method.

Phases	N. tested chemicals	Assessment	Protocol used	Main protocol updates as compared to previous protocol
Phase 0	5 non-coded chemicals	Transferability	1.30e	- Time from start of exposure to start of measurement: within 2 to 5 seconds.
Phase I	10 coded chemicals	WLR & BLR	1.51e	- Reference control acceptance criteria: TEER plateau level between 10% to 30% inclusive. - Measurements conducted at room temperature ($18^{\circ}\text{C} \leq T \leq 30^{\circ}\text{C}$). - Time from start of exposure to start of measurement: within 2 seconds.
Phase II	10 coded chemicals	BLR	1.61e	- Reference control acceptance criteria: TEER plateau level between 10% to 40% inclusive. - Measurements conducted at ambient temperature ($22^{\circ}\text{C} \leq T \leq 30^{\circ}\text{C}$). - Procedural clarifications (e.g. chemicals solubilisation, clarifying procedures for volatilizing chemicals; clarifying procedures in case of technical issues).
Phase III	36 coded chemicals	BLR & PC	1.71e	- Reference control acceptance criteria: TEER plateau level 10% or more (upper level to be decided at the end of phase III of the validation study). - Measurements conducted at $28 \pm 2^{\circ}\text{C}$.
In-house data	132 noncoded chemicals (including 96 chemicals not tested in phase III)	PC		57 out of the 96 chemicals were tested according to the latest version of the protocol, i.e., with measurements conducted at $28 \pm 2^{\circ}\text{C}$.
Final protocol			1.80e	- Inclusion of a section on applicability domain. - Inclusion of pH measurement of 2.5% solutions. - Procedural clarifications for dissolving chemicals.

BLR: between-laboratory reproducibility; PC: predictive capacity; WLR: within-laboratory reproducibility.

4.4. Within- and between-laboratory reproducibility

Based on results obtained with 10 coded chemicals tested in Phase I, the within-laboratory reproducibility (WLR) was found to meet the success criteria established by the VMT (see Table 3). The 10 chemicals comprised 6 classified (two Cat. 1 and four Cat. 2) and 4 No Cat. test chemicals

according to the UN GHS classification scheme (Anon., 2017a). The Validation Study report notes that such a number of chemicals was chosen based on the “*biostatistician’s opinion about the statistical validity of the number of test chemicals used for the (EURL-)ECVAM validation study for skin sensitization*” (chapter 3.3.2.2, p. 21 of Anon., 2017a). The PRP would have appreciated having further statistical justification for the number of chemicals (10) used to assess the within-laboratory reproducibility, and whether such number was considered sufficient by the VMT.

The between-laboratory reproducibility (BLR) was also found to meet the success criteria established by the VMT (see Table 3). The BLR was evaluated based on the results obtained with 36 coded chemicals from phase III comprising 24 classified (i.e., 12 Cat. 1 and 12 Cat. 2) and 12 No Cat. test chemicals according to the UN GHS classification scheme. Phase II results were not considered in the evaluation of BLR due to the fact that temperature was found to affect reproducibility, and that during that phase temperatures varied from 22°C to 30°C, whereas it was controlled to be 28±2°C during phase III (Anon., 2017a). Although the number of UN GHS No Cat. chemicals tested to establish BLR was smaller than the number of UN GHS classified chemicals, this is justifiable in the case of Vitrigel-EIT which is proposed as an initial test in a bottom-up testing strategy approach, and therefore should demonstrate appropriate sensitivity (i.e., low rate of false negative predictions).

Table 3. Within- and between-laboratory reproducibility of the Vitrigel-EIT method.

Phases	N. tested chemicals	Assessment	WLR			BLR	VMT success criteria
			Lab A	Lab B	Lab C		
Phase I	10 coded chemicals	WLR & BLR	80% (8/10)	100% (10/10)	90% (9/10)	-	≥ 80% WLR
Phase III	36 coded chemicals	BLR & PC	-	-	-	92% (33/36)	≥ 80% BLR

BLR: between-laboratory reproducibility; Lab A: Hatano Research Institute, Food and Drug Safety Center – FDSC (Hatano, Kanagawa); Lab B: Bozo Research Center –BRC (Tokyo); Lab C: Daicel Corporation (Himeji, Hyogo); PC: predictive capacity; VMT: validation Management Team; WLR: within-laboratory reproducibility.

4.5. Selection of test chemicals

The PRP considered that a representative set of chemicals was selected to assess the between-laboratory reproducibility and the predictive capacity of the Vitrigel-EIT method. It is noted that due to the limited sample size in phase III, additional data obtained in-house for further 57 chemicals tested at 28 ± 2°C (Yamaguchi et al., 2016) were used to assess the predictive capacity of the assay. Results obtained with the 57 test chemicals were added to the dataset obtained with the 36 chemicals tested in phase III of the validation study, resulting in a total of 93 test chemicals used to assess the predictive capacity of the Vitrigel-EIT assay (Anon., 2017a).

The 93 chemicals used to assess the predictive capacity of the assay comprised 29 Cat. 1, 31 Cat. 2 and 33 No Cat. chemicals according to the UN GHS classification scheme (see appendix 8.13 of Anon., 2017a), having a balanced distribution of the three UN GHS categories of eye hazard. Furthermore, the selected chemicals had representation of both solids and liquids (see Table 4), and covered a wide range of chemistries.

Chemicals from phases I, II and III were tested coded, whereas chemicals tested in house were tested non-coded. It is noted that an overlap of 5 (out of 10) chemicals existed between phases I and II, an overlap of 4 chemicals existed between phases I (out of 10 chemicals) and III (out of 36 chemicals), and an overlap of 9 chemicals existed between phases II (out of 10 chemicals) and III (out of 36 chemicals). The PRP considers this overlap to be helpful as it allowed to demonstrate improvement of reproducibility through the progression of protocol modifications as described in Table 2.

Table 4: Representation of liquids, solids and the various UN GHS categories of the selected chemicals.

		UN GHS Cat. 1	UN GHS Cat. 2	UN GHS No Cat.	Total
Phase I	Liquids	1	2	2	5
	Solids	1	2	2	5
	Total	2	4	4	10
Phase II	Liquids	1	3	1	5
	Solids	3	0	2	5
	Total	4	3	3	10
Phase III	Liquids	4	9	7	20
	Solids	8	3	5	16
	Total	12	12	12	36
In-house	Liquids	7	9	20	36
	Solids	10	10	1	21
	Total	17	19	21	57

4.6. Predictive capacity

The predictive capacity of Vitrigel-EIT was initially assessed based on the 36 chemicals tested coded in phase III of the validation study. In a second step 57 chemicals tested in a non-coded manner inhouse were added to this analysis, resulting in a total of 93 test materials (Anon., 2017a). Based on the outcome of this analysis, a reduced applicability domain of the assay was proposed by the VMT as described in section 4.9 of this report. When applying the reduced applicability domain, 17 test chemicals (of the 93) were excluded representing eight chemicals from the phase III of the validation

study (4 Cat. 1, 3 Cat. 2 and 1 No Cat.) and nine chemicals from the in-house tested dataset (3 Cat. 1 and 6 Cat. 2). As a consequence, the predictive capacity of the reduced applicability domain of the Vitrigel-EIT was based on a total of 76 test chemicals as shown in Table 5. The 76 test chemicals represented 22 Cat. 1, 22 Cat. 2 and 32 No Cat. chemicals according to the UN GHS classification scheme (cf. appendix 8.13 of the validation report). Out of these, 28 were tested coded during phase III of the validation study (8 UN GHS Cat. 1, 9 UN GHS Cat. 2 and 11 UN GHS No Cat. chemicals) and 48 were tested non-coded in-house (14 UN GHS Cat. 1, 13 UN GHS Cat. 2 and 21 UN GHS No Cat. chemicals).

Table 5. Predictive capacity of the Vitrigel-EIT method.

	All tested chemicals				Reduced Applicability Domain			
	Phase III 36 coded chemicals		In-house 57 non-coded chemicals	Combined 93 chemicals	Phase III 28 coded chemicals		In-house 48 noncoded chemicals	Combined 76 chemicals
	Per laboratory	Overall*			Per laboratory	Overall*		
Sensitivity	75.0 – 83.3% (18-20/24)	79.2% (19/24)	86.1% (31/36)	83.3% (50/60)	88.2 – 94.1% (15-16/17)	88.2% (15/17)	96.3% (26/27)	93.2% (41/44)
Specificity	41.7% (5/12)	41.7% (5/12)	85.7% (18/21)	69.7% (23/33)	36.4% (4/11)	36.4% (4/11)	85.7% (18/21)	68.8% (22/32)
Accuracy	63.9 – 69.4% (23-25/36)	66.7% (24/36)	86.0% (49/57)	78.5% (73/93)	67.9 – 71.4% (19-20/28)	67.9% (19/28)	91.7% (44/48)	82.9% (63/76)

* Based on a majority of predictions from the participating laboratories.

Only three false negatives (out of 44 UN GHS classified test chemicals) were found with the reduced applicability domain, all of which were *in vivo* UN GHS Cat. 2 test chemicals. These included the waxy, water insoluble solid camphene (CAS 79-92-5; UN GHS Cat. 2B), α -hexylcinnamaldehyde (CAS 10186-0; UN GHS Cat. 2A) and 6-methylpurine (CAS 2004-03-07; UN GHS Cat. 2B). It is noted that no UN GHS Cat. 1 was under-predicted as No Cat. when applying the reduced applicability domain of Vitrigel-EIT method. Furthermore, the false negative rate obtained with the Vitrigel-EIT for its proposed reduced applicability domain is within the overall probability of about 12% of chemicals identified by the *in vivo* Draize eye test as either UN GHS Cat. 2 or UN GHS No Cat. in a repeated *in vivo* test, due to the method's inherent within-test variability (OECD GD 263, 2017; OECD TG 492, 2015).

4.7. Data supporting the validity of the assay

The data presented to the PRP did support the conclusions from the validation study report.

4.8. Accordance with the principles of Good Laboratory Practices

Based on the information available to the PRP, the study was conducted in the spirit of GLP.

4.9. Applicability Domain

The test method is proposed to be used for the identification of UN GHS No Cat. test chemicals as an initial test in a bottom-up testing strategy approach. Based on the results of the validation and inhouse studies, a reduced applicability domain was proposed by the VMT (Anon., 2017a), in which two exclusion criteria are proposed as follows:

- exclude $\text{pH} \leq 5.0$ based on 2.5% solution
- exclude solids having both a $\log P \geq 2.5^1$ and a density of $< 0.95 \text{ g/cm}^3$ or $> 1.10 \text{ g/cm}^3$.

A possible rationale provided by the VMT for the proposed reduced applicability domain is the fact that acidic substances were reported to influence TEER measurements (Yamaguchi et al., 2016), and the fact that substances having $\log P \geq 2.5$ and a density of $< 0.95 \text{ g/cm}^3$ or $> 1.10 \text{ g/cm}^3$ may be water-insoluble.

4.10. Proficiency chemicals

A list of 10 proficiency chemicals divided into 3 UN GHS Cat. 1, 3 UN GHS Cat. 2 and 4 UN GHS No Cat. has been proposed (Appendix 8.9 of Anon., 2017a). The peer-review panel welcomed the proposed list of proficiency chemicals, but was of the opinion that such a list might require further consideration during the process of regulatory acceptance. In particular, the PRP believes that it is important to ensure that the proposed proficiency chemicals have reproducible results between laboratories and between runs, and that it is based on the most up-to-date version of the protocol. In that regard, chemicals that may merit further consideration include camphene (CAS 79-92-5), α hexylcinnamaldehyde (CAS 101-86-0), toluene (CAS 108-88-3) and 3-methoxy-1,2-propanediol (CAS 623-39-2).

4.11. Performance Standards

The PRP agreed that performance standards can aid the regulatory acceptance process following the peer-review, but are not needed at the present stage for the PRP evaluation.

¹ It was noted by the VMT that $\log P$ values used to define the applicability domain were obtained at 20°C or 25°C. Furthermore it was noted that the $\log P$ value at 28°C is rarely different from the $\log P$ value at 20°C, as the impact of temperature is generally of only 0.001-0.01 per 1°C of the $\log K_{ow}$ value.

4.12. Advantages in terms of time, costs and animal welfare

A comparison between the Vitrigel-EIT and adopted alternative test methods for eye hazard assessment has been provided in the validation report in terms of time, practicality, costs, mechanistic relevance, limitations and predictive capacity (Anon., 2017a). Furthermore, Table 6 shows the predictive capacity of the Vitrigel-EIT method as compared to the alternative test methods currently adopted for the identification of UN GHS No Cat. test chemicals for eye hazard assessment.

In particular, the PRP noted that the Vitrigel-EIT is based on a different mechanism of action compared to the alternative assays currently adopted since it assesses the epithelial barrier function based on a three dimensional culture system composed of human corneal epithelium.

Table 6. Comparison of Vitrigel-EIT predictive capacity to the alternative test methods currently adopted for identification of UN GHS No Cat. test chemicals.

	BCOP (OECD TG 437)	ICE (OECD TG 438)	STE* (OECD TG 491)	RhCE (OECD TG 492)	Vitrigel-EIT**
Accuracy	69% (135/196)	82% (125/152)	90% (92/102)	80-84% (n>112)	83% (63/76)
False positive rate (1-specificity)	69% (61/89)	33% (26/79)	19% (9/48)	28-37% (n>55)	31% (10/32)
False negative rate (1-sensitivity)	0% (0/107)	1% (1/73)	2% (1/54)	4-5% (n>57)	7% (3/44)

* Reduced applicability domain as proposed within TG 491;

** Reduced applicability domain as proposed by the VMT (see section 4.9).

4.13. Completeness of data and documents

The PRP appreciated the transparency with which all the Vitrigel-EIT assay material was presented, in particular regarding the protocol modifications during the various phases of the assay validation. The PRP agreed that the data and documents provided were complete and sufficient to evaluate the Vitrigel-EIT validation study.

4.14. Validation study management and conduct

The PRP considered that the Vitrigel-EIT underwent a validation study in accordance with internationally accepted principles (OECD Guidance Document 34, 2005) and following a modular approach to validation (Hartung et al., 2004).

4.15. Other considerations

The PRP agreed that the Vitrigel-EIT method does not seem to pose issues related to intellectual property rights. Indeed, the validation study report states that (Anon., 2017a):

- all components and reagents used in the test method are commercially available;
- the HCE-T cells can be globally distributed from RIKEN BioResource Center;
- the Vitrigel-EIT method is available without any restriction by its intellectual property rights;
- Vitrigel is registered trade mark of National Agriculture and Food Research Organization (Tsukuba, Japan).

5. Conclusions

The PRP concluded that the Vitrigel-EIT method, when based on its proposed applicability domain, can be considered as a valid assay for the identification of test chemicals not requiring classification and labelling for eye irritation or serious eye damage (UN GHS No Cat. chemicals). This is valid for the limited applicability domain of test chemicals having pH > 5.0 based on 2.5% solution; and excluding solids having both a log P \geq 2.5 and a density of < 0.95 g/cm³ or > 1.10 g/cm³.

6. Acknowledgements

The PRP is grateful to the members of the VMT for their hard work and to JaCVAM for their support in setting up and hosting meetings in Japan, as well as for the setting up of several telephone conferences.

7. References

Vitrigel-EIT Validation management team (2017a). Validation study of the Vitrigel-EIT method as an alternative to *in vivo* eye irritation testing. Study report, version 2.0 last revised in August 2017, 64 pp.

Vitrigel-EIT Validation management team (2017b). Standard protocol for the Vitrigel-EIT method. Version 1.80e received in May 2017, 14pp.

Araki-Sasaki, K., Ohashi, Y., Sasabe, T., Hayashi, K., Watanabe, H., Tano, Y., Handa, H. (1995). An SV40-immortalized human corneal epithelial cell line and its characterization. *Investigative Ophthalmology & Visual Science* 36, 614–621. <https://www.ncbi.nlm.nih.gov/pubmed/7534282>.

Cooper-Hannan, R., Harbell, J., Coecke, S., Balls, M., Bowe, G., Cervinka, M., Clothier, R., Hermann, F., Klahm, L.K., de Lange, J., Liebsch, M., Vanparys, P. (1999). The principles of good laboratory practice: application to *in vitro* toxicology studies. *ATLA* 27, 539–577. <https://www.ncbi.nlm.nih.gov/pubmed/25487864>.

Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M., Hoffmann, S., Janusch Roi, A., Prieto, P., Sabbioni, E., Scott, L., Worth, A., Zuang, V. (2004). A modular approach to the ECVAM principles on test validity. *ATLA* 32, 467–472. <https://www.ncbi.nlm.nih.gov/pubmed/15656771>.

Kim, C. W., Go, R. E., Lee, G. A., Kim, C. D., Chun, Y. J., Choi, K. C. (2016). Immortalization of human corneal epithelial cells using simian virus 40 large T antigen and cell characterization. *Journal of Pharmacological and Toxicological Method*, 78, 52–57. <https://www.ncbi.nlm.nih.gov/pubmed/26631824>.

OECD (2005). Series on Testing and Assessment, Number 34: Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. Organisation for Economic Cooperation and Development, Paris, France. ENJ/JM/MONO(2005)14. Available at: <http://www.oecd.org/env/ehs/testing/series-testing-assessment-publications-number.htm>.

OECD (2015). Guideline for the Testing of Chemicals No. 492. Reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage. Organisation for Economic Cooperation and Development, Paris, France. Available at: <http://www.oecd.org/env/testguidelines>.

OECD (2017). Series on Testing and Assessment, Number 263: Guidance Document on an Integrated Approach on Testing and Assessment (IATA) for Serious Eye Damage and Eye Irritation. Organisation for Economic Cooperation and Development, Paris, France. ENJ/JM/MONO(2017)15. Available at: <http://www.oecd.org/env/ehs/testing/series-testing-assessment-publications-number.htm>.

Takezawa, T., Nishikawa, K., Wang, P. C. (2011). Development of a human corneal epithelium model utilizing a collagen vitrigel membrane and the changes of its barrier function induced by exposing eye irritant chemicals. *Toxicology In Vitro* 25, 1237–1241. <https://www.ncbi.nlm.nih.gov/pubmed/21641988>.

Yamaguchi, H., Kojima, H., Takezawa, T. (2013). Vitrigel-eye irritancy test method using HCE-T cells. *Toxicological Sciences* 135, 347–355. <https://www.ncbi.nlm.nih.gov/pubmed/23872712>.

Yamaguchi, H., Kojima, H., Takezawa, T. (2016). Predictive performance of the Vitrigel-eye irritancy test method using 118 chemicals. *Journal of Applied Toxicology* 36, 1025–1037. <https://www.ncbi.nlm.nih.gov/pubmed/26472347>.

Yamasaki, K., Kawasaki, S., Young, R. D., Fukuoka, H., Tanioka, H., Nakatsukasa, M., Quantock, A. J., Kinoshita, S. (2009). Genomic aberrations and cellular heterogeneity in SV40-immortalized human corneal epithelial cells. *Investigative Ophthalmology & Visual Science* 50, 604–613. <https://www.ncbi.nlm.nih.gov/pubmed/18824731>.